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ABSTRACT 
Three studies are described in this report First, the effect of intravenous 
administration of the steroidal drug isoflupredone acetate on healthy lactating 
dairy cows and lactating dairy cows with mastitis induced using gram-negative 
bacterial endotoxin was investigated. Cows were randomly assigned to one of four 
treatment groups: untreated controls, isoflupredone acetate only, mastitis only, 
and mastitis plus isoflupredone acetate. Isoflupredone acetate was given to treated 
groups at a dose of 20 mg intravenously, once. Mastitic cows receiving treatment 
were given isoflupredone acetate after the development of mammary swelling and 
an increase in rectal temperature of at least 1° Celsius. When compared with 
untreated mastitic controls, cows with endotoxin-induced mastitis treated with 
isoflupredone acetate did not exhibit measurable differences in heart rate, rectal 
temperature, rumen motility, or changes in mammary gland surface area in the 14 
hours following the administration of intramammary endotoxin, nor did they have 
significantly different milk production following the mastitic episode. Healthy cows 
treated with isoflupredone acetate had a higher heart rate over the 14 hours 
following drug administration than did untreated healthy controls, but this was 
likely caused by repeated blood sampling of the drug-treated cows for another 
study. 
In the second study, somatic cell counts and flow cytometric analysis of 
cytokeratin-positive epithelial cells in the milk of lactating Holstein cows were 
performed before and 12 hours after the induction of mastitis using purified 
bacterial endotoxin. Prior to the induction of mastitis, the mean percentage of cells 
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that were cytokeratin-positive was 4.18% ± 1.05, and the mean total number of 
cytokeratin-positive cells per milliliter of milk was 7,711 ± 2,575 . Twelve hours 
after the induction of mastitis, çytokeratin-positive cell percentages and numbers 
in bovine milk were significantly increased; the mean percentage of çytokeratin-
positive cells was 40.63 % ± 10.23, and the mean number of çytokeratin-positive 
cells per milliliter of milk was 2,954,554 ± 877,719. Treatment with flunixin 
meglumine or isoflupredone acetate after the development of clinical signs of 
mastitis did not mitigate the increase in somatic cell count or çytokeratin-positive 
cells in milk in the first 12 hours following endotoxin administration. 
Finally, the effects of flunixin meglumine and isoflupredone acetate were 
compared in lactating Holstein dairy cows with mastitis induced by the 
intramammaiy administration of purified bacterial endotoxin. Drugs were 
administered to cows following the development of mammaiy swelling in the 
affected gland and a rectal temperature of 40 °C or greater. Heart rate, rectal 
temperature, and rumen motility were recorded hourly for 14 hours following the 
intra mammary administration of endotoxin. Milk production was evaluated for five 
days before and ten days following the day of mastitis induction and drug 
treatment Neither drug decreased milk production loss nor mammaiy surface 
swelling when compared to untreated mastitic controls. Both drugs reduced the 
mean heart rate in treated groups over the 14 hours following endotoxin 
administration, when compared to untreated mastitic controls. Animals treated 
with flunixin meglumine also had increased rumen motility and decreased rectal 
temperature over the same time period, when compared to untreated mastitic 
controls or mastitic cows treated with isoflupredone acetate. 
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Taken together, these studies suggest that neither the NSAID flunixin 
meglumine nor the corticosteroid drug isoflupredone acetate ameliorate milk 
production losses in cows with endotoxin-induced mastitis when they are 
administered following the onset of clinical signs, nor do they decrease the 
magnitude of sloughing of mammaiy epithelial cells into the milk in the acute 
phase of endotoxin-induced mastitis. Both drugs may, however, provide some relief 
from the pain of mastitis, as evidenced by the decrease in heart rate in cows 
treated with either drug following the development of endotoxin-induced mastitis. 
Only flunixin meglumine was found to alleviate fever associated with endotoxin-
induced mastitis. Until it is known whether relief of fever is beneficial or 
detrimental in naturally occurring cases of infectious mastitis, it is not possible to 
infer that one agent would be superior to the other in the treatment of such cases. 
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CHAPTER 1. GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation is presented as an introductory chapter, three chapters 
corresponding to papers submitted or accepted for publication, and a chapter of 
general conclusions. All of the papers included address the central research 
question of this dissertation: What are the effects of steroidal and non-steroidal 
anti-inflammatory drugs on endotoxin-induced mastitis in lactating dairy cows? 
The second and fourth papers describe the physiologic effects of a corticosteroid 
drug and a non-steroidal inflammatory drug in cows with endotoxin-induced 
mastitis. The study presented in the third chapter describes the effects of both 
drugs on epithelial cells in cows' milk. An Appendix describes data analysis for the 
flow cytometry method used in conducting the research presented in Chapter 3. 
The coauthors of the submitted manuscripts contributed in the following 
ways: Michael D. Apley was the Major Professor and involved in all aspects of the 
studies including study design, data collection and analysis. Doug Jones was 
integral in flow cytometry method development, the performance of flow cytometry 
and the analysis of flow cytometry data. 
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Literature Review 
Part One: Models of Endotoxic Mastitis 
Mastitis due to infection of the mammary gland or glands remains a costly 
disease to the daiiy industry and an ongoing topic of investigative research. There 
are numerous pathogens implicated in infectious bovine mastitis; this literature 
review and the research described herein focus on endotoxic mastitis caused by 
coliform bacteria, the most common causative agents in severe clinical cases of 
mastitis. (Hogan, Smith et al. 1989) The term "coliform" is used to describe gram 
negative bacteria including Escherichia coli, Klebsiella species, and Enterobacter 
species. (Rebhun 1995) 
Mammary gland infection with gram-negative coliform organisms may result 
in a mild, moderate or severe case of mastitis. Mild or moderate disease is 
characterized by localized mammary swelling and abnormal milk, with or without 
the presence of systemic signs such as depression and fever. These mild or 
moderate cases may be resolved without any treatment of the cow. (Erskine, Tyler 
et al. 1991) Coliform mastitis may also be quite severe in its manifestation, 
particularly in cows suffering immunosupression, which is commonly observed in 
dairy cows around the time of calving. (Cai, Weston et al. 1994) Many of the 
detrimental effects of coliform infection are due to the endotoxin produced by 
coliform bacteria. (Lohuis, Verheijden et al. 1988) Cows affected with severe 
coliform mastitis are frequently recumbent, with a hot, swollen mammary gland, 
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watery abnormal milk in the affected gland, fever or hypothermia, diarrhea, rumen 
stasis, anorexia, and dehydration. More than 30 percent of severely affected cows 
may become bacteremia, (Wenz, Harrington et al. 2001) and concurrent 
hypocalcemia is common. (Rebhun 1995) Severe endotoxic mastitis may be fatal to 
the cow. Cows that do survive commonly suffer sequelae such as chronic active or 
subclincal infection, agalactia in one or more quarters, or musculoskeletal damage 
as a result of prolonged recumbency. (Rebhun 1995) 
Because coliform mastitis can be so severe in its manifestation and 
consequences, much research has been done to investigate how to prevent and 
treat it The goal of therapy is to preserve the life of the cow and minimize harmful 
sequelae. In addition to antimicrobial therapy to eliminate the causative pathogen 
from the mammary gland and systemic circulation, anti-inflammatory drugs have 
been investigated in the hope that they may reduce mortality, preserve milk 
production, and alleviate the clinical signs associated with coliform mastitis. 
Research into the therapy of endotoxic mastitis has been conducted using 
various models, including: 1) naturally occurring cases of endotoxic mastitis due to 
spontaneous infection, 2) endotoxic mastitis artificially induced by introducing live 
bacteria, usually Escherichia coli, into the mammaiy gland, and 3) endotoxic 
mastitis induced by the administration of purified bacterial endotoxin. 
Mastitis due to natural infection would be expected to provide the most 
reliable data about the effects of various therapies for endotoxic mastitis; after all, 
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it is for natural infection that we are hoping to develop better treatment through 
research. Unfortunately, difficulties are encountered in using natural infection to 
research the therapy of endotoxic mastitis. Naturally occurring endotoxic mastitis 
is progressive over time, but some cases will ultimately become more severe than 
others. As it is impossible to know the time or size of microbial inoculation of a 
naturally occurring case of mastitis, it is quite difficult to determine where in the 
progression of disease each cow is when first examined. For example, a moderately 
affected cow may have already attained the greatest severity of disease she will 
suffer during the mastitic episode, or she may be in the process of developing 
severe, even life-threatening disease. One way to avoid this variation would be to 
treat only cases of endotoxic mastitis defined as severe. This can certainly be done, 
but severe naturally occurring endotoxic mastitis is sporadic in nature, (Sargeant, 
Scott et al 1998) and it would take either a long duration of time or a large 
number of participating farms to accumulate enough naturally occurring cases to 
provide the statistical power necessary to demonstrate the effect of a treatment 
that is moderately beneficial. 
Because of the difficulties associated with using natural infection to study 
the therapy of coliform mastitis, induced mastitis models have frequently been 
used instead. One approach has been to induce infection using a known number of 
colony forming units of coliform bacteria, most commonly Escherichia colt The 
advantage of this approach is clear; it is an infectious model of an infectious 
disease. Unfortunately, the variability one encounters in clinical disease due to 
natural infection is also present in induced infection. Intramammaiy 
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administration of the same number of colony forming units of bacteria to a number 
of cows can result in a "great variation in duration and severity of clinical signs". 
(Lohuis, Schukken et al. 1990) This is likely due to variations in 
immunocompetence between cows and resulting variations in the speed and 
magnitude of bacterial killing When cows had approximately 104 colony forming 
units of Escherichia coli (of a strain isolated from a clinical case) infused into their 
left rear quarter, some animals were mildly affected with mastitis as a result; these 
animals had mean peak bacterial concentrations of 3.3 x 101 Colony Forming Units 
(CFU) per ml of milk at 12 hours post administration, and they all had 
bacteriologically negative milk at 29 hours post administration. (Lohuis, Schukken 
et al. 1990) Other cows in the same study developed severe illness following 
administration of the same strain and number of bacteria; these animals had mean 
peak bacterial numbers of 1.2 x 109 CFU per ml of milk at 18 hours post infection 
and continued to have more than 1000 CFU per ml of milk through the last 
sampling time at 125 hours post-infection. There were also large variations in the 
magnitude of milk production loss between cows. In addition to the large amount 
of variability in clinical disease produced by induction of mastitis using live 
bacteria, use of live bacteria also compels the investigator to decide whether or not 
to give antibiotics, as has usually been done, and if so when in the course of 
disease to administer the drug, which type of antimicrobial drug to administer, and 
what dosing regimen to use. 
Some of the drawbacks encountered when using an induced infection model 
may be avoided by using a non-infectious model of endotoxic mastitis in which 
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purified Lipopolysaccharide endotoxin from Escherichia coli is administered into 
one or more mammary glands. There are several advantages to this approach. 
Unlike the induced infection model, the response to intra mammaiy endotoxin 
challenge is generally quite consistent between cows, (Tyler, Welles et aL 1994) as 
the amount of endotoxin to which each cow is exposed is not dependent on the 
quality of her immune response. Furthermore, the issue of whether and when to 
administer antimicrobial therapy becomes moot as no infectious agent is 
administered. Additionally, the course of the clinical response is brief; although 
typically used doses of endotoxin result in markedly increased rectal temperature, 
depression, and decreased rumen motility, these clinical signs are short-lived and 
resolve within 12 to 24 hours. (Lohius, Leeuwen et aL 1989) Milk production losses 
generally resolve within a few days, (Hoeben, Burvenich et al. 2000) but in one 
high-dose study mean milk production never returned to pre-challenge levels. 
(Oostveldt, Tomita et aL 2002) Fatalities using the endotoxin-induced mastitis 
model were not reported in any of the many such studies reviewed. 
The endotoxin-induced mastitis model does have its limitations, however. 
One limitation is the same as an advantage it provides- the illness is generally 
short-lived and there have been no documented fatalities. Although this feature is 
beneficial to the preservation of research animals and their milk production, it is 
not an accurate reflection of the severe potential consequences of natural infection. 
Furthermore, qualitative differences between the physiological response of cows 
with mastitis due to coliform infection and mastitis due to intramammaiy 
endotoxin administration have been demonstrated. For example, in one study 
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blood was taken from cows during the acute phase of mastitis induced using either 
Escherichia coli bacteria or endotoxin. (Oostveldt, Tomita et aL 2002) After 
incubating the blood samples for three hours, the percentage of apoptotic 
neutrophils in the blood was increased in cows with E.coli mastitis when compared 
to non-mastitic cows, but this effect was not observed in cows with endotoxin-
induced mastitis. There were also many similarities between the two models in the 
study cited above; E. coli and endotoxin both caused milk somatic cell count, rectal 
temperature, and percentage of immature neutrophils in the blood to increase, and 
both models caused milk production and total leukocyte count to decrease. These 
changes were more rapid, more severe and of shorter duration in cows with 
endotoxin-induced mastitis. Both models have also been demonstrated to raise 
levels of Tumor Necrosis Factor alpha in plasma and milk, and levels of nitric oxide 
in milk. (Blum, Dosogne et al. 2000) Again, these effects tend to peak earlier in 
endotoxin-infused cows than in cows infused with E. coli bacteria. 
Hoeben et al also found that endotoxin-induced mastitis produced 
physiological changes more quickly than mastitis induced using E coli bacteria. 
(Hoeben, Burvenich et al. 2000) Overall mille production loss was greater in 
infected cows, which suffered "substantial" losses in both inflamed and non-
inflamed quarters, but it was more acute in endotoxin infused cows, which suffered 
only "negligible' losses in the non-inflamed quarters. As in other studies, both 
models increased plasma levels of Tumor Necrosis Factor alpha in blood plasma. 
Hoeben hypothesized that there existed "differences in kinetics, composition and 
amounts of different cytokines released in the mammaiy gland and subsequently 
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absorbed into the circulation" between the infectious and endotoxin models. This 
hypothesis is consistent with the literature, at least in terms of amounts and 
kinetics of cytokine release in the two models, if not the composition of those 
cytokines, which has thus far not been demonstrated to be different- One unusual 
aspect of Hoeben's study was that cows with endotoxin-induced mastitis did not 
have decreased reticulorumen motility during the resulting episode of mastitis; this 
finding is inconsistent with the work reported in this dissertation. 
Finally, work at the cellular level has demonstrated different effects of 
endotoxin and infection with Escherichia coli bacteria on the epithelium of the 
mammaiy gland. Studies in which endotoxin or E. coli was administered into the 
mammaiy gland, followed by slaughter of animals and microscopic examination of 
the affected gland, revealed that endotoxin caused inflammation and edema of the 
mammary epithelium, while bacterial infection resulted in necrosis and sloughing 
of epithelial cells from the basement membrane. The effects of mastitis on the 
mammary epithelium are discussed in more detail in a later section of this review. 
Overall, administration of purified bacterial endotoxin has produced a 
consistent result: clinical mastitis of short duration but high intensity, with 
moderate local and systemic clinical signs and acute but short-lived losses in milk 
production. This uniformity of response is useful in a research setting, as are the 
limited milk production loss and low risk of fatality, but these qualities of the 
model also make it dissimilar to the severe naturally acquired infections that are 
the target of therapies under investigation. For this reason, endotoxin-induced 
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mastitis should be seen as a useful tool for preliminary investigation, but not a 
foolproof replication of "the real thing". It would be justified to expand investigation 
of therapies that appear promising using the endotoxin-induced mastitis model 
into research trials involving naturally occurring cases of mastitis. Still, the utility 
of the endotoxin model as a less expensive, consistent and useful tool for 
preliminary investigation has been established. 
Part Two- Anti-Inflammatory Drugs and Endotoxic Mastitis 
Anti-Inflammatory drugs can be divided into two major categories; 
corticosteroids and non-steroidal anti-inflammatoiy drugs (NSAIDs). Both NSAIDS 
and glucocorticoids have been investigated as therapeutic agents in the treatment 
of endotoxic mastitis. The two types of anti-inflammatory drugs have some 
pharmacologic similarities and some differences. 
Corticosteroid drugs are described as being either primarily 
mineralocorticoid (regulating electrolyte metabolism) or glucocorticoid (regulating 
carbohydrate metabolism) in their activity. Corticosteroid drugs used for anti­
inflammatory therapy have predominantly or entirety glucocorticoid activity. 
(Schimmer and Parker 2001) In addition to their anti-inflammatory activity, 
glucocorticoids affect the cardiovascular system, the central nervous system, the 
digestive system, the hypothalamic-pituitary-adrenal axis, and protein, fat and 
bone metabolism. (Ferguson and Hoenig 2001) 
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Glucocorticoids are among the most commonly used drugs in veterinary 
medicine. (Ferguson and Hoenig 2001) Their 21-carbon molecular structure 
includes three 6-carbon rings and one 5-carbon ring. (Schimmer and Parker 2001) 
Glucocorticoid drugs are lipid-soluble and therefore are able to penetrate cell 
membranes to access glucocorticoid receptors, which are present in the cytosol. 
The unbound glucocorticoid receptor is complexed with heat shock protein 90, 
which is released upon binding to the glucocorticoid and may play a role in 
glucocorticoid anti-inflammatoiy activity. (Ferguson and Hoenig 2001) The 
hormone-receptor complex then travels into the nucleus of the cell, where it can 
directly or indirectly alter gene expression. Production of some inflammatory 
mediators, such as chemokines, cytokines, and adhesion molecules, is decreased. 
Production of anti-inflammatoiy molecules called lipocortins (also called annexins) 
is increased. Lipocortins act by inhibiting the enzyme Phospholipase As, which 
catalyzes the conversion of cell membrane phospholipids into arachidonic acid 
(5,8,11,14-Eicosatetraenoic acid). Consequently, there is decreased production of 
the inflammatory products of arachidonic acid metabolism: prostaglandins, 
leukotrienes, and platelet activating factor. 
Glucocorticoid drugs also inhibit the production of the enzyme cyclo-
oxygense 2 (COX2), found at sites of inflammation, which functions in the 
production of the inflammatory prostaglandin PGG2 from arachidonic acid. 
(Schimmer and Parker 2001) The unstable PGG2 is quickly converted to PGH2, 
which is also an unstable intermediate. PGG2 and PGH2 are called endoperoxides, 
have a half life in humans of 4 to 5 minutes, and are able to cause aggregation of 
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platelets and contraction of smooth muscle. PGG2 and FGH2 may ultimately be 
converted to PGE2, PGI2 PGFao, or thromboxanes. (Ninneman 1988) Prostaglandin 
E compounds increase vascular permeability, induce vasodilation, are leukotactic, 
may cause pain, stimulate the release of lysosomal enzymes, and elevate body 
temperature. (Ramwell 1973) Although they inhibit the inflammation-induced 
production of COX2, glucocorticoids have not been observed to inhibit production 
of çyclo-oygenase 1 (COX1), a constitutive emyme which catalyzes the production 
of prostaglandins such as the PGI2 in the kidneys, which serves an anti-
hypotensive function, and PGE2 in the gastric mucosa, which regulates acid 
secretion. (Boothe and Mealey 2001; Morrow and Roberts 2001) The wide variety of 
prostaglandin effects may be explained by the wide variety of prostaglandin 
receptors; PGE2, for example, has at least five known receptor types. (Morrow and 
Roberts 2001) It is important to note that the current understanding of the 
functions of the cyclo-oxygenase enzymes is incomplete; recent work has described 
homeostatic functions of COX2 and a role for COX1 in the resolution of the 
inflammatory process. (Morita 2002) Membrane-associated glucocorticoid receptors 
have also been identified, and may be responsible for the rapid effects of 
glucocorticoids, such as changes in cellular membranes in the treatment of shock. 
(Ferguson and Hoenig 2001) 
The glucocorticoid drug Isoflupredone, also called 9-alpha 
fhioroprednisolone, is a fluorinated prednisolone molecule, with the fluorine 
molecule at carbon number nine. Dexamethasone is also fluorinated at carbon 
number 9, but cortisone, hydrocortisone, prednisone, and prednisolone are not 
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Isoflupredone is described as having glucocorticoid potency 10 times greater than 
hydrocortisone and about one third that of dexamethasone, but these relative 
potencies have not been confirmed in the treatment of inflammation associated 
with mastitis. (McDonald 1988) Isoflupredone is unique among these compounds 
because it does not cause abortion in pregnant cattle at any stage of gestation. 
(Mohammedsadegh 1994) The drug is commonly used in the United States to treat 
dairy cattle for ketosis and inflammatory conditions, and it has FDA approval for 
such use [Package Insert, Pharmacia Animal Health, Kalamazoo, MI]. The drug 
does have some mineralocorticoid activity; repeated administration of high doses 
has been associated with electrolyte imbalances in lactating dairy cows, specifically 
hypokalemia. (Siehnan, Sweeney et al. 1997) 
In contrast to the glucocorticoids, which exert their anti-inflammatory 
actions at several points along the inflammatory cascade, the anti-inflammatory 
activity of NSAID drugs is more focused. They also have a markedly different 
structure: all of the commonly used NSAIDs are organic acids incorporating one, 
two or three benzene rings. (Roberts and Morrow 2001) Acetominophen has a 
number of properties that make it different from the other NSAIDs; as it is not used 
to treat cattle, acetaminophen will not be included in this review of the actions of 
NSAIDs. 
The mechanism of NSAID activity is the inhibition of prostaglandin 
production by the cyclo-oxygenase enzymes. Unlike glucocorticoids, which inhibit 
the production of COX2 only, NSAIDs commonly used in food animal medicine are 
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active on both COXl and COX2 enzymes. Some new NSAID drugs used in humans 
and small animals are selective for action primarily on the COX2 enzyme, but none 
of the COX2 selective drugs has yet been approved or adopted for use in cattle. 
Unlike glucocorticoids, NSAIDs inhibit the activity, not the production, of the cyclo-
oxygenase enzymes. 
Aspirin covalently and permanently modifies both COXl and COX2, 
resulting in a duration of clinical effect that is related to the speed with which new 
cyclo-oxygenase molecules are generated. The modification of the COX2 enzyme by 
binding of aspirin not only inhibits the production of pro-inflammatory 
prostaglandins, it also causes the enzyme to produce the anti-inflammatory 
product 15-epilipoxin A*. (Hardman, Limbird et al. 2001) The other NSAIDs are 
competitive reversible inhibitors of cyclo-oxygenase; their duration of action is 
related to the rate of clearance of the drug from the body. Although some NSAID 
drugs have been found to exert other anti-inflammatory activities, inhibition of 
COX enzymes is still considered to be the most important mechanism of action of 
the NSAIDs. (Roberts and Morrow 2001) 
Flunixin meglumine is an NSAID that has previously been investigated as a 
therapy for endotoxic mastitis, as described below. Its chemical name is 3-pyridine-
carboxylic acid, and its structure contains 2 benzene rings. It has FDA approval for 
the indications of fever, inflammation, and endotoxemia in cattle [Package insert, 
Banamine®, Schering-Plough]. 
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As NSAIDs and glucocorticoids have different structures and mechanisms of 
action, they might be expected to also have different effects when used as anti-
inflammatoiy agents in the treatment of endotoxic mastitis, and this has proven to 
be the case. The comparative effects of NSAIDs and steroids in the treatment of 
mastitis are discussed in some detail in the following chapter and will therefore 
only be summarized here. 
Both glucocorticoid and NSAID drugs have been shown to reduce local 
inflammation of the mammary gland (evaluated externally) when administered 
systemically prior to the onset of clinical signs of mastitis induced using bacteria or 
bacterial endotoxin. (Carroll, Schalm et al 1965; Anderson, Smith et al. 1986; 
Lohuis, Werven et al 1991) Studies evaluating NSAIDs in the treatment of induced 
mastitis have demonstrated a reduction in rectal temperature following the 
systemic administration of these agents. (Anderson, Smith et al 1986; Anderson 
and Hunt 1989; Lohuis, Werven et aL 1991; Morkoc, Hurley et al 1993) The effects 
of systemic glucocorticoids on fever have been inconsistent, with studies 
demonstrating either increased or decreased febrile response in treated animals 
when compared to untreated mastitic controls. The dose of dexamethasone that 
decreased fever, 220 mg for a 500 kg cow, was more than seven times higher than 
the 30 mg per cow dose that increased fever (Lohuis, Leeuwen et aL 1988; 
Anderson and Hunt 1989). 
Research investigating the question of whether anti-inflammatory drugs 
improve the likelihood of recovery of cows from endotoxic mastitis due to coliform 
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infection has been uncommon and inconclusive. A study done in goats did not 
indicate that treatment with the NSAID flunixin meglumine or the glucocorticoid 
dexamethasone was detrimental to the clearance of infectious E coli bacteria from 
experimentally challenged mammary glands. (Anderson, Hunt et al. 1991) One 
study did claim an increased odds ratio of recovery in cows with naturally 
occurring E.ooli mastitis treated repeatedly with systemic administration of the 
NSAID drug ketoprofen. (Shpigel, Chen et aL 1994) This study may not be relevant 
to severe endotoxic mastitis, however, as eligibility criteria for admission to the 
study were a 25% drop in millf production and "typical clinicopathological changes 
in milk and the udder". "Typical" was undefined, and a complete lack of systemic 
clinical signs did not exclude cows from the study. Recovery was defined as cows 
that returned to at least 75% of pre-mastitis milk production. These same 
parameters were used in another study by the same author, which concluded that 
the NSAIDs phenybutazone and dipyrone also increase the odds of recovery from 
acute mastitis. (Shpigel, Winkler et al. 1996) Both of these studies compared cows 
receiving anti-inflammatoiy treatment to the same historical control group, so both 
could be confounded with the same time effects. 
To this author's knowledge, no other published research has claimed 
improved recovery in cows treated with non-steroidal anti-inflammatory drugs. 
Completely prospective clinical trials, using contemporary controls, have shown no 
benefit to treatment with the NSAIDs flunixin or phenylbutazone in naturally 
occurring cases of clinical endotoxic mastitis. One study compared therapy with 
flunixin to therapy with intravenous fluids alone or intravenous fluids plus 
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flunixin; the odds of survival were the same in all three groups, with survival 
defined as neither dying nor being culled due to the mastitic episode. (Green, 
Green et al. 1997) All cows admitted to the study also received standardized 
therapy with antimicrobial drugs and calcium borogluconate. Another study 
compared therapy with saline solution to therapy with flunixin or phenylbutazone, 
and did not find any significant effects of drug treatment on the likelihood of 
survival or the speed and magnitude of milk production recovery in cows that did 
survive. (Dascanio, Mecher et al. 1995) Both studies randomly allocated cows to 
treatment groups (drugs, saline solution, or both) as they were enrolled, and both 
studies had admissions criteria that included both mammary and systemic clinical 
signs such as weakness, signs of shock, fever or depression; cows without systemic 
manifestations of disease were not admitted to either study. 
After survival of the cow, the parameter that is likely to be most important to 
the dairy producer with a cow affected by toxic mastitis is subsequent milk 
production. Aside from the work described above using a historical control group, 
studies done using naturally occurring cases or mastitis models have not shown 
systemic use of NSAIDs to be of benefit to subsequent milk production in cows 
with endotoxic mastitis. (Anderson, Smith et al 1986; Dascanio, Mecher et aL 
1995) It has been reported that intra mammary administration of the NSAID drug 
ibuprofen significantly decreased milk loss in cows with endotoxin-induced 
mastitis, however, this was reported in abstract form, as a preliminary result and 
no detailed follow-up report has been published to date, so the methods used in 
the study cannot be evaluated. (Hatfield, Harmon et al. 1984) 
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The effect of the systemic administration of the glucocorticoid drug 
dexamethasone on milk production has been evaluated in cows with mastitis 
induced using E.coli bacteria and found to reduce losses in milk production. 
(Lohuis, Leeuwen et aL 1988) The same drug, in combination with the 
antimicrobial drugs ampicillin and polymixin E, was also shown to enhance 
recovery of milk production in cows with endotoxin-induced mastitis. (Ziv, Shem 
Tov et aL 1998) The inclusion of antimicrobial drugs in the treatment of endotoxin-
induced mastitis in this study is unusual, as there is no infectious process at work 
in endotoxin-induced mastitis. Incubation of polymorphonuclear leukoctes from 
bovine mammary glands with drugs from the same classes Ziv et al used (the beta-
lactam drug dicloxacillin and the polymixin drug polymixin B) did not enhance 
viability of the cells or phagocytic activity when compared to control cells incubated 
with phosphate buffered saline. (Nickerson, Paape et aL 1985) In fact, alterations 
in normal cell morphology were noted in the cells incubated with polymixin B. Any 
benefit to mammary epithelial cell function or survival from these antimicrobial 
drugs that did not benefit other cells from the mammary gland, and may have 
damaged them, seems unlikely. It would be more reasonable to assume that the 
beneficial effect on milk production in the study by Ziv et al was due to the 
dexamethasone, as it had also demonstrated such benefit in an infectious mastitis 
model. It is important to note that in both of the studies in which dexamethasone 
had a beneficial effect on milk production in mastitic cows, the drug was not 
administered in response to the development of clinical signs; rather it was given 
either immediately after intramammaiy challenge (both studies) or at a set time 
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afterward (Ziv et al). This would be impossible to do in the case of a natural 
infection, as one cannot determine which cows have been infected until they 
manifest clinical signs. No experimental studies were found in which drugs were 
administered as they would be in practice, in response to the development of 
clinical signs. Several studies have been done using intra mammary administration 
of glucocorticoid drugs to treat mastitis; however no studies located by this author 
reported measurement of mflk production following such administration. (Hatfield, 
Harmon et aL 1984; Merminod and Schaellibaum 1985; Lohius, Leeuwen et al. 
1989) 
Only one previous study has investigated the effect of the steroidal drug 
isoflupredone acetate in cows with endotoxic mastitis. (Carroll, Schalm et aL 1965) 
This study, done more than 35 years ago, evaluated isoflupredone acetate as a 
treatment for mastitis induced by intramammary administration of the coliform 
bacteria Aerobacter aerogenes. The drug was given prior to the onset of clinical 
signs of mastitis by the intramuscular or intramammary route, with the 
intramammary dose totaling 500 mg and the intramuscular dose totaling 600 mg 
per cow. The current label dose is 10 to 20 mg per cow. This high dose was found 
to have depressant effects on milk production, just as a supra-therapeutic dose of 
dexamethasone did in a later study. (Anderson and Hunt 1989) Other clinical 
effects of treatment with isoflupredone were equivocal; there was "some possibility" 
that local edematous swelling was reduced in treated cows. Prior to the research 
reported herein, there had not been any published studies of isoflupredone acetate 
at the label dose as a therapy for endotoxic mastitis. 
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Part Three: Examination nf Epithelial flmllR in Mille 
Much of the research investigating cells in cows' milk during and after 
endotoxic mastitis has been concerned with immune cells. It has been determined, 
for example, that the primary factor affecting the likelihood of recovery of a cow 
from coliform mastitis is the speed and magnitude of neutrophil recruitment to the 
infected mammary gland. (Hill 1981) The magnitude of the leukocyte response to 
endotoxic mastitis is reflected in a marked increase in the number and percentage 
of neutrophils in the mammary gland and milk during the acute phase of mastitis. 
(Paape, Wergin et al 1981) 
The percentage and total numbers of epithelial cells in milk have generally 
been considered to drop during the acute phase of mastitis as numbers of 
leukocytes, particularly neutrophils, increase dramatically. (Paape, Wergin et al. 
1981) However, studies have also demonstrated epithelial cell sloughing into the 
milk as early as one hour following the administration of a very large number (109 
colony forming units) of Escherichia coli into the mammary gland. (Frost, Hill et al. 
1980) Microscopic examination of the mammary glands of cows administered this 
high dose of bacteria revealed epithelial necrosis and sloughing one hour following 
the administration of the bacteria, which worsened by two hours post-infection, 
and was followed by an influx of neutrophils. This work suggests that the observed 
increase in the neutrophil population in milk may be preceded by an increase in 
the population of epithelial cells in the milk as they are sloughed early in the onset 
of clinical mastitis. In later work by the same author, using more moderate doses 
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of E. coli (50 or 200 CFU), epithelial cell necrosis and sloughing took a longer time 
to develop, and was again followed by an "intense inflammatory response". (Frost, 
Hill et al. 1982) The lesions caused by epithelial necrosis and sloughing are a 
short-lived phenomenon; they may be repaired in as few as five hours by migration 
of remaining epithelial cells across the undamaged basement membrane. (Brooker, 
Hill et aL 1981) 
As described earlier, dexamethasone has been observed to protect milk 
production in cows with endotoxic mastitis; such an effect has not been 
convincingly demonstrated for flunixin meglumine. No explanation for the 
protective effect of dexamethasone on milk production has been established. The 
anti-inflammatory or gluconeogenic functions of glucocorticoid drugs would be 
two obvious candidates for explaining how dexamethasone exerts its protective 
function on milk production during mastitis; however, there must also be some 
cause for the inhibition of milk production observed when dexamethasone is 
administered to cows without mastitis. (Hartmann and Kronfeld 1973; Anders son 
and Olsson 1984) Anti-inflammatory or glucoeneogenic effects would seem 
extremely unlikely to cause decreased milk production in any circumstance. An 
hypothesis was conceived that would explain both the reported protective effects on 
milk production by glucocorticoids in mastitic cows and their detrimental effects on 
milk production in healthy cows. Glucocorticoid drugs inhibit Phosphlipase As and 
promote lipocortin production, both of which inhibit breakdown of the cell 
membrane into arachidonic acid. Glucocorticoid drugs also interfere with 
dissolution of connective tissue and cells, and they may stabilize lysosomal 
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membranes. (Ferguson and Hoenig 2001) If glucocorticoid drugs have these effects 
on the membranes of the secretory cells of the mammary epithelium, they would be 
expected to promote the milk production effects observed for dexamethasone in 
both healthy and mastitic cows. In healthy cows, stabilization of cell membranes 
would decrease mille secretion, as the apical membrane of the cell must be able to 
separate and form micelles during the milk secretion process. Glucose uptake 
might also be depressed by decreased function of the cell membrane. During 
mastitis, however, these effects of glucocorticoid drugs would be expected to be 
beneficial, as stabilization of lysosomal membranes and cell membranes might help 
secretory epithelial cells in the mammary gland survive the endotoxic insult 
encountered in mastitis. With the resolution of the mastitic episode and 
elimination of the drug, cows treated with dexamethasone, if this hypothesis is 
correct, would be expected to have more functional, undamaged secretory cells 
remaining in their mammary glands than untreated controls, and they would 
consequently have more robust milk production following the episode of mastitis. 
In order to test the hypothesis that a glucocorticoid drug would increase 
mammary epithelial cell survival through an episode of mastitis, without 
slaughtering or performing biopsies on any of the cows to directly observe 
mammary epithelium, it was decided to observe numbers of epithelial cells in the 
milk before and after the administration of purified baterial endotoxin. Cows had 
either no drug treatment, treatment with the NSAID flunixin meglumine, or 
treatment with the glucocorticoid drug isoflupredone acetate. If the glucocorticoid 
drug did increase survival of epithelial cells in endotoxin-induced mastitis, it could 
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reasonably be expected that cows treated with isoflupredone acetate would shed 
fewer epithelial cells in their milk during the acute phase of mastitis. 
Epithelial cells in milk have been identified using a number of methods 
including light microscopy with Wright's stain or monoclonal antibody-linked stain, 
and transmission electron microscopy. (Paape and Miller 1988; Leitner, Shoshani 
et al. 2000) Paape's study indicated a good agreement between Wright's stain and 
anti-cytokeratin antibody linked stain in the number of cells identified as epithelial 
cells using light microscopy combined with staining. The study described in this 
dissertation identified mammary epithelial cells using a combination of anti-
cytokeratin antibody linked fluorescent staining and flow cytometry, using a 
variation on previously described techniques for analysis of epithelial cells in cows' 
and goats' milk. (Harrington, Besser et al. 1997; Boutinaud, Rulquin et aL 2002) 
The technique used to preserve and stain milk samples is described in detail in 
Chapter 3. Following preservation and staining, milk cell samples were analyzed 
using a FACScan Flow Cytometer (Becton-Dickinson, Union, NJ). 
Flow cytometry is a tool for analyzing the characteristics of cells in 
suspension as they flow past a point of observation. The cells to be analyzed are 
suspended in solution, which is introduced into the center of a wider diameter flow 
of sheath solution. This results in laminar flow of the solution past the observation 
point, with the cells passing by one at a time but very quickly. At the observation 
point, a laser beam is focused upon each cell. Optic lenses and computer software 
are used to measure and describe the forward scatter of the laser off the cells, or 
23 
the light that is scattered between approximately 0.5 and 10 degrees from the 
original direction of the laser beam. The intensity of this forward scatter light is 
measured and translated into an approximation of the diameter of the cell under 
examination. Another lens is placed perpendicularly to the light source and used to 
measure the intensity of perpendicular light scatter intensity, which is used to 
measure the quantity of granular structures within the cell Fluorescence 
intensities may also be measured at several different wavelengths, to quantify the 
uptake of various fluorescent stains by the cell Light scatter and fluorescence are 
measured simultaneously as each cell passes through the laser light beam. 
(Shapiro 1988) Examples of the forward scatter, side scatter, and fluorescence 
properties of the cells examined in the research described in this dissertation are 
given in Appendix 1. 
The objectives of the studies reported in the following chapters were: 
1) To describe the physiologic and mille production effects of the steroidal drug 
isoflupredone acetate on cows with endotoxin-induced mastitis, when the 
drug was given systemically at the label dose after the appearance of clinical 
signs; 
2) To measure the changes in epithelial cell populations in the milk of cows 
with endotoxin-induced mastitis, and to evaluate whether such changes 
were affected by systemic treatment of the cows with anti-inflammatory 
drugs; 
24 
3) To compare the physiologic and milk production effects of the NSAID drug 
flunixin meglumine to the effects of the corticosteroid drug isoflupredone 
acetate in cows with endotoxin-induced mastitis. 
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CHAPTER 2. PHARMACODYNAMICS OP ISOFLUPREDONE ACETATE IN AN 
ENDOTOXIN-INDUCED MASTITIS MODEL 
A Paper Accepted for Publication by the Journal of Dairy Science 
Sarah A. Wagner, Michael D. Apley 
Abstract 
The effect of intravenous administration of the steroidal drug isoflupredone 
acetate on lactating dairy cows with mastitis induced using gram-negative bacterial 
endotoxin was investigated. Cows were randomly assigned to one of four treatment 
groups: untreated controls, isoflupredone acetate only, mastitis only, and mastitis 
plus isoflupredone acetate. Isoflupredone acetate was given to treated groups at a 
dose of 20 mg intravenously, once. Mastitic cows receiving treatment were given 
isoflupredone acetate after the development of clinical signs. When compared with 
untreated mastitic controls, cows with endotoxin-induced mastitis treated with 
isoflupredone acetate did not exhibit measurable differences in heart rate, rectal 
temperature, rumen motility, or changes in mammary gland surface area in the 14 
hours following the administration of intramammary endotoxin. Healthy cows 
treated with isoflupredone acetate had a higher heart rate over the 14 hours 
following drug administration than did untreated healthy controls. When compared 
with untreated mastitic controls, cows treated with isoflupredone acetate did not 
exhibit statistically significant differences in milk production following endotoxin-
induced mastitis. 
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Introduction 
Mastitis is a common affliction of modern dairy cows and a major cause of 
lost income in the dairy industry. Temporary or permanent decreases in milk 
production may result from inflammatory damage to the mammary gland caused 
by mastitis. Antimicrobial drugs can inhibit or destroy mastitis-causing bacteria, 
but antimicrobial drugs do not generally have any anti-inflammatory activity, thus 
they do not act directly to limit inflammatory damage to the mammary gland 
(Nickerson et al, 1986). 
Researchers in the past have investigated whether therapy of gram-negative 
endotoxic mastitis with steroidal or non-steroidal anti- inflammatory drugs is 
beneficial. Typically, investigators have administered a variety of anti-inflammatory 
drugs concurrently with or shortly after the induction of mastitis using bacteria or 
purified bacterial endotoxin, but before the development of systemic clinical signs. 
Unfortunately, in a clinical setting it is not possible to identify and treat 
mastitic cows prior to the development of clinical signs of mastitis. The goal of this 
project was to test the hypothesis that the steroidal drug isoflupredone acetate may 
limit milk production loss and reduce clinical signs in cows with endotoxin-
induced mastitis when the drug is given parenteral^ after the development of 
clinical signs. In the United States, the steroidal drug isoflupredone acetate is 
labeled for the treatment of inflammatory conditions in dairy cows. 
Materials and Methods 
This protocol was approved by the Committee on Animal Care at Iowa State 
University. 
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Study Population 
Thirty-two Holstein cows from the Iowa State University Dairy in Ankeny, 
Iowa, were used in this study. They were selected based on the following criteria: 
30 to 70 days into second or greater lactation, no clinical mastitis in the current 
lactation, no drug treatment in the previous 30 days, and no abnormalities on 
physical examination. 
Group Assignment and Randomization Procedures 
Cows were randomly assigned to one of four treatment groups: untreated 
controls, drug administration only, mastitis only, and mastitis plus drug 
administration. Randomization was achieved by assigning a two digit random 
number from a random number list, read in sequence from a random starting 
point, to each treatment group on each day. Cows were then assigned to a 
treatment group by ranking each cow from lowest to highest farm identification 
number, then assigning them to the group with the randomly assigned number of 
the same rank. In order to minimize day effects on clinical outcomes, one cow from 
each of the four treatment groups was enrolled in the trial on each of eight trial 
days. Two of the 32 selected cows were removed from the study due to lameness 
on the day they were scheduled to participate, leaving a total of 30 cows enrolled in 
the study. Ultimately there were eight cows in each treated group and six cows in 
the control group, as both cows removed due to lameness had been assigned to the 
untreated control group. All clinical work for this project was conducted between 
September 2000 and April 2001. 
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Housing and Husbandry 
On trial days, cows were kept in a small barn where they were accustomed 
to spending time while undergoing treatments and routine examinations such as 
pregnancy diagnosis. They had unlimited access to water and a total mixed ration 
composed primarily of com silage and dry hay, formulated for lactating dairy cows. 
Cows were caught in headlocks for the hourly recording of clinical observations, 
but were allowed to roam freely in the bam at other times. The cows were milked at 
their normal 12-hour interval. 
Induction of Mastitis 
Cows assigned to treatment groups with mastitis had a negative bacterial 
culture 72 hours before the induction of mastitis and a negative California Mastitis 
Test in the treated quarter on the day of their participation the study. The 
California Mastitis Test on the other three quarters had either negative or trace 
reaction immediately before the induction of mastitis. 
Mastitis was induced in the left front quarter of selected cows unless there 
was a trace positive California Mastitis Test in that quarter on the day of the study, 
in which case the right front quarter was used. Mastitis was induced in selected 
quarters by intramammary administration of 0.1 mg purified Lipopolysaccharide 
(LPS) from Escherichia coli B4:0111 (Sigma-Aldrich, St.Louis, MO) in 20 mL sterile 
isotonic saline solution. 
Clinical mastitis was defined as measurable swelling of the affected 
mammary gland, defined as an increase above baseline measurements of 
mammary surface area, and a rise in rectal temperature of at least 1 °C above the 
baseline measurement taken prior to the administration of LPS. Cows that did not 
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meet these criteria for development of clinical mastitis following the infusion of LPS 
into a mammary gland were removed from the study. 
Eighteen groups of cows were cultured in order to qualify the nine groups of 
cows enrolled in the study. One group of four cows was removed from the study on 
the day of participation because the cows in the groups given intramammary 
endotoxin did not develop clinical mastitis as defined in this study. 
Clinical Variables 
Clinical variables recorded hourly for all treatment groups included rectal 
temperature by electronic thermometer, heart rate by auscultation for 15 seconds 
with a stethoscope, and number of rumen contractions per two minutes by 
auscultation for two minutes with a stethoscope. Cows in groups with mastitis also 
had mammary skin surface area measured hourly. This was done using a 
modification of the technique of making two indelible marks on the udder skin and 
measuring the distance between the marks using calipers, as described by Bywater 
et al (1988). In this study, four indelible marks were made on the udder skin using 
a rectangular plastic template measuring 100 mm by 120 mm, and the distance 
between the marks for each side of the rectangle and both diagonals were 
measured using a flexible plastic ruler. Total area of the rectangle at each time 
point was calculated as follows: The rectangular area being measured was divided 
by the two diagonals into to four triangles, and the area of each triangle was 
calculated based on the length of its three sides using Heron's Formula, which 
states that the area of a triangle with sides of lengths a, b, and c is equal to 
Vs(s - a%s - ax* - e), where s equals a * b * c .  T h e  a r e a s  o f  t h e  f o u r  t r i a n g l e s  w e r e  
2 
summed to total the overall rectangular surface area. This method allowed surface 
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area measurements to accurately reflect expansion that occurred outward from the 
initial plane of measurement, in addition to expansion within the two dimensions 
of the created rectangle. 
Study Design 
One cow from each treatment group was enrolled in the study on each trial 
day, in order to minimize day effects on outcome variables. 
Beginning immediately after morning milking, each cow was examined and 
had baseline clinical observation values recorded. Cows in groups with endotoxin-
induced mastitis were prepared for udder surface area measurement by clipping 
the hair of the mammary gland quarter to be treated and placing four black marks 
on that quarter using a plastic template and a permanent marker. The four 
experimental groups were then treated as follows (Figure IV. 
Cows in the untreated control group had clinical variables recorded for 14 
more hourly observations (15 total observations including baseline). 
Cows in the group receiving only drug treatment were given 20 mg 
isoflupredone acetate (Predef 2X, Pharmacia Animal Health, Kalamazoo, MI) one 
time by jugular venipuncture soon after the recording of baseline observations. 
Clinical variables were recorded for 14 more hourly observations. Cows in this 
group also had nine blood samples taken by jugular venipuncture over the next 24 
hours for a concurrent pharmacokinetic study. 
Cows in the group with endotoxin-induced mastitis but no drug treatment 
had LPS infused into one quarter shortly after the recording of baseline variables. 
Mammary surface area measurements and other clinical variables were recorded 
for 14 more hourly observations. 
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Cows in the group receiving drug treatment following the development of 
clinical mastitis had LPS infused into one quarter shortly after the recording of 
baseline variables. Cows that subsequently developed clinical signs of mastitis as 
defined above received 20 mg of isoflupredone acetate one time by jugular 
venipuncture as soon as possible after the hourly observation at which they were 
noted to have developed clinical mastitis. Observations were continued for at least 
12 hours following the establishment of clinical mastitis. This group also had nine 
blood samples collected by jugular venipuncture over a 24-hour period for a 
concurrent pharmacokinetic study. 
Milk Production 
Milk weight data used in this study were collected electronically. Each cow 
in the study wore a computer chip bearing her farm identification number on a 
neck strap. This identification number was read by a scanner as each cow entered 
the milking parlor and used to record the cow's milk production at each milking. 
Cows enrolled in this study had twice-daily milk weights recorded for the week 
prior and three weeks following the day of participation in the study. 
Statistics 
All statistical analyses for this study were performed using the JMP 
statistical software program (SAS Institute, Caiy, North Carolina). The study design 
provided a power of greater than 0.80 to detect a one-day difference of 10 pounds 
in daily milk weight between groups. Analysis of baseline clinical variables was 
performed using analysis of variance. Subsequent clinical variables and four-day 
baseline milk production data were analyzed using multivariate analysis of 
variance, which accounts for repeated measurements over time. Statistical 
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significance was designated a priori as a P value less than or equal to 0.05. 
Baseline clinical observations were considered covariates for statistical analysis of 
clinical variables following treatment, in order to compensate for variation in mean 
baseline measurements between groups. 
Initial analysis of milk production during the recovery period using 
multivariate analysis of variance for repeated measures revealed an interaction 
between time and treatment Further statistical analysis was therefore done using 
analysis of variance separately for each day of the recovery period. Dunnett's 
method was used to correct the tendency toward type 1 error when comparing 
treatment groups individually to the control group. 
Due to failure of the scanner at the milking parlor entrance to read the cow's 
identification number, milk weight data were not recorded for every cow at each 
time point used in the data analysis..Missing milk weights were replaced with an 
average of the previous and subsequent milk weights. For this herd, the bias 
introduced by using morning weights to estimate evening weights and vice versa is 
minimal, as mean morning and evening milking weights for all cows in this study, 
calculated using only observed weights, varied by less than one percent. One cow 
from the untreated mastitis group was missing all but one milk weight 
measurement, and one cow from the same group was missing more than half of the 
milk weights to be used for analysis. These two cows were removed from statistical 
analysis of milk production, but their clinical observation data were complete and 
were used in analysis of treatment effects. Among cows with milk weight data used 
for statistical analysis, one cow from the control group (no mastitis or drug 
treatment) was missing 12 of the 24 observations used. Five cows were missing 
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four to six data points, three cows were missing three data points, seven cows were 
missing two data points, four cows were missing one data point, and eight cows 
had mille weights for all time points used in the statistical analysis. The 
replacement of missing milk weights with the average of previous and subsequent 
weights may reduce the "within-cow* variation in the data, which may increase the 
likelihood of differences between treatment groups being found to be statistically 
significant. 
Result* 
Rumen contractions (Figure 2) 
For all groups, baseline observations were not significantly different (P = 
0.8556). Both drug treated (P = 0.0413) and untreated (P < 0.01) cows with mastitis 
had significantly decreased rumen motility over time as compared to the control 
group. Drug treatment did not significantly effect the magnitude of rumen motility 
depression in mastitic cows (P = 0.27). The group of cows receiving drug treatment 
alone did not have decreased rumen motility as compared to the untreated control 
group (P= 0.4105). 
Heart rate (Figure 3) 
Baseline heart rate for the four groups was not different (P = 0.8611). Cows 
receiving only drug treatment had a higher heart rate over time (P < 0.01) than 
untreated controls. Groups with mastitis had the same mean heart rate over time 
regardless of whether they were treated with isoflupredone acetate or not (P = 
0.4524). Both mastitic groups had higher mean heart rates than the group 
receiving only the drug (mastitis plus drug treatment, P = 0.0245, mastitis only P = 
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0.0112) and higher mean heart rates than the untreated control group (P < 0.01 for 
both mastitic groups). 
Rectal Temperature (Figure 4) 
Mean baseline temperatures for all groups were not significantly different (P 
= 0.6674). Temperature changes over time were the same for all cows with mastitis 
(P = 0.5307) and for all cows without mastitis (P= 0.7663), regardless of drug 
treatment status. Mastitic cows with or without drug treatment had higher mean 
temperatures over time than did control cows or cows receiving only drug 
treatment (P < 0.01 for all groups). 
Mammary Surface Area (Figure 5) 
Changes in mammary surface area over the 14 hours following the 
introduction of LPS into the mammary gland were not different for drug treated 
and untreated mastitic cows (P = 0.097). 
Milk Production (Figure 6) 
Mean baseline m file production for the four days preceding the initiation of 
the trial was not different between treatment groups (P = 0.5544). 
There were no statistically significant differences in milk weights between any 
groups for the day of endotoxin challenge and drug administration (P = 0.0858). On 
the following day, both treatment groups with mastitis had lower milk production 
than the control group (P < 0.05). By the second day following the induction of 
mastitis, there were once «gain no statistically significant differences in milk 
production between the groups (P > 0.05). For the drug treated group without 
mastitis, there was no significant difference in milk production when compared to 
the control group at any time point (P > 0.05). 
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Discussion 
Previous work investigating the effect of anti-inflammatory steroid drugs in 
cows with endotoxic mastitis has largely been focused on the effect of drug 
administration prior to or concurrent with the induction of mastitis. Carroll et al 
(1965) gave 9-alpha fluoroprednisolone acetate (also called isoflupredone acetate) 
using a variety of regimens, then induced mastitis using Aerobacter aeroaenes 
bacteria introduced into the mammary gland. In that study, doses of 50 mg and 
100 mg of 9-alpha fluoroprednisolone were given once intramuscularly, 250 mg 
was given twice intramuscularly at a ten-hour interval, 200 mg was given thrice 
intramuscularly at 12-hour intervals, or 500 mg was given by the intra mammary 
route into each front quarter once. Single dose regimens were administered 
concurrently with the intramammaiy administration of bacteria, while multiple 
dose regimens had the final dose administered concurrently with the induction of 
mastitis. Nine-alpha fluoroprednisolone decreased mammary swelling following the 
induction of mastitis and caused decreased milk production prior to the induction 
of mastitis in multiple-dose regimens. Milk production beyond 48 hours following 
the mastitic episode was not recorded, but might not be relevant to today's high 
producing daiiy cows in any case; the cows enrolled in this study 37 years ago 
were producing between 25 and 45 pounds of milk per day, much less than typical 
modern dairy cows. 
Administration of 30 mg dexamethasone intramuscularly to cows 
concurrently with the induction of mastitis using Escherichia coli bacteria affected 
physiological parameters and milk production in treated cows (Lohuis et al, 1988). 
43 
When compared to saline-treated controls, cows receiving dexamethasone had 
reduced neutropenia, reduced local signs of inflammation, diminished decreases in 
rumen amplitude, and increased rectal temperature during the acute phase of 
mastitis. Milk production over the 14 days following induction of mastitis was 
markedly increased in cows receiving dexamethasone treatment, when compared to 
saline-treated controls. Dexamethasone also decreased the shift in milk production 
ratio from rear to front quarters in this study in which all cows were infected in a 
rear quarter. This suggests that the drug directly affected the mastitic gland, rather 
than facilitating a shift in production to the unaffected glands. 
Further work by Lohuis et al (1989) examined three different steroidal 
drugs. Flumethasone at a dose of 5mg and dexamethasone at a dose of 30 mg were 
given intramuscularly at the same time as induction of mastitis using purified 
bacterial endotoxin. Prednisolone was given at a dose of 40 mg by the 
intramammaiy route at zero, two or four hours following the administration of 
endotoxin. Intramammaiy administration of prednisolone two hours after 
administration of endotoxin abolished the febrile response and diminished the 
endotoxin-induced rise in heart rate. Cows given intramuscular steroid drugs in 
this experiment had less mammary swelling, smaller increase in rectal 
temperature, smaller increase in heart rate, and less severe neutrophilia and 
lymphopenia when compared to untreated mastitic controls. Milk production 
effects were not reported. 
An endotoxin-induced mastitis model was used to investigate the effect of a 
very high intravenous dose of 0.44 mg/kg dexamethasone; for a typical 500 kg 
dairy cow this would be 220 mg, more than seven times the dose used by Lohuis et 
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al (Anderson, KL and Hunt, E, 1989). Dexamethasone was administered two hours 
after the introduction of endotoxin into the mammary gland. It was stated that 
there was clinically detectable mammary swelling at the time of drug 
administration, but not that there were detectable systemic abnormalities at that 
time. Cows given dexamethasone in this study did not achieve mean rectal 
temperatures above 39.2 °C, in marked contrast to the increased rectal 
temperatures observed in cows receiving a much lower dose of dexamethasone in 
the previously mentioned study. 
The purpose of the study reported here was to investigate whether a 
moderate dose of the steroidal drug isofiupredone acetate could ameliorate milk 
production losses and clinical signs when used as it might be used in a clinical 
setting- at the approved label dose, in a cow with systemic signs of illness. 
Isofiupredone acetate does not have a labeled indication for intravenous 
administration, but such use is not prohibited. The results obtained when the drug 
was given after the development of clinical signs were not entirely consistent with 
the results of the earlier studies, which generally administered steroid drugs prior 
to the development of clinical signs. Unlike previous studies, inhibition of rumen 
motility (measured in this study using the crude method of auscultation) and 
increased mammary gland surface area were not alleviated. Isofiupredone acetate 
also did not affect febrile changes in rectal temperature in treated cows with 
mastitis; it neither increased the magnitude of change as a moderate dose of 
dexamethasone had done previously, nor decreased the magnitude of change as a 
large dose of dexamethasone had done. Isofiupredone did not decrease heart rate 
in treated cows with mastitis as compared to untreated cows with mastitis. An 
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unanticipated finding in this study was that cows receiving drug treatment only, 
without mastitis, had a higher heart rate over the observation period than did 
untreated controls. This may be partly or entirely due to stress, as the cows 
receiving drug treatment had jugular venipuncture performed eight times during 
the 14-hour observation period for a concurrent pharmacokinetic study. 
Isofiupredone acetate did not affect milk production in mastitic or healthy 
cows in this study. Mastitic cows with or without drug treatment had significantly 
decreased milk production for one day following the induction of mastitis. This 
drop in mean production was approximately 30 percent of baseline for both groups 
on the first day after the trial, and it had rebounded to approximately a ten percent 
loss for both groups by the next day. This is a considerably milder effect than was 
achieved with live bacterial model used by Lohuis et al in 1988. In that study, the 
induction of mastitis using live Escherichia coli bacteria resulted in milk production 
being 48 to 100% reduced in untreated cattle fourteen days after the initiation of 
mastitis. Because the model used in the current study caused only mild and 
transient milk production loss, drug treatment effects would have to be very strong 
or study power (cow numbers) would have to be quite high to detect an effect of 
drug treatment on milk production. Isofiupredone acetate has less than half the 
anti-inflammatory potency of dexamethasone (Langston, 1993). The unfortunate 
loss of all data for two cows due to lameness and milk production data for two 
cows due to computer malfunction reduced the power of this study to detect any 
significant treatment effects. 
In conclusion, the data from this study suggest that the steroidal drug 
isofiupredone acetate, when administered at the label dose after the onset of 
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clinical signs in an endotoxin-induced mastitis model, does not affect the course of 
clinical signs in the acute phase of mastitis or subsequent milk production. 
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CHAPTER 3. FLOW CYTOMETRIC ANALYSIS OF CYTOKERATIN-POSITIVE 
CELLS IN MILK FOLLOWING ENDOTOXIN-INDUCED MASTITIS 
A Paper Submitted to the Journal of Daily Science 
S. A. Wagner, D.E. Jones, and M. D. Apley 
Abstract 
Somatic Cell Counts and flow cytometric analysis of cytokeratin-positive 
cells in the milk of lactating Holstein cows were performed before and 12 hours 
after the induction of mastitis using purified bacterial endotoxin. Epithelial cells 
are the only cells in bovine milk that are expected to be cytokeratin-positive. Prior 
to the induction of mastitis, the mean percentage of cells that were cytokeratin-
positive was 4.18%, and the mean total number of cytokeratin-positive cells per 
milliliter of milk was 7,711. Twelve hours after the induction of mastitis, 
cytokeratin-positive cell percentages and numbers in bovine milk were significantly 
increased; the mean percentage of cytokeratin-positive cells was 40.63 %, and the 
mean number of cytokeratin-positive cells per milliliter of milk was 2,954,554. 
Treatment with steroidal or non-steroidal anti-inflammatory drugs after the 
development of clinical signs of mastitis did not mitigate the increase in somatic 
cell count or cytokeratin-positive cells in milk in the first 12 hours following 
endotoxin administration. 
Text 
Epithelial cells are considered to be a normal component of milk from cows 
without mastitis; estimates of the prevalence of epithelial cells as a percentage of 
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total somatic cells in normal milk have varied from 0 to 65%. When a cow develops 
endotoxic mastitis, epithelial cells in the mammary gland are damaged and may be 
sloughed into the milk (Frost and Hill, 1982). It was hypothesized that treatment of 
cows with anti-inflammatory drugs following the development of clinical endotoxic 
mastitis might result in decreased damage to epithelial cells in the mammary 
gland, resulting in a decreased number of epithelial cells sloughed into the milk 
during the acute phase of mastitis. 
Twelve non-pregnant cows between 30 and 60 days in milk in their second 
or greater lactation were selected for use in this study based on a history of no 
mastitis in the current lactation, no drug treatment in the previous 30 days, 
negative California Mastitis Test on all four quarters, and negative bacterial culture 
on the front 2 quarters. Milk samples for analysis of Somatic Cell Count and 
cytokeratin-positive cells were collected at the morning milking, and again just 
prior to the next milking 12 hours later. 
Endotoxic mastitis was induced in one front quarter of each cow as soon as 
possible after the morning milking by intramammaiy administration of 100 pg 
purified lipolysachharide (LPS) from Escherichia coli strain Oil 1:B4 (Sigma-Aldrich, 
St Louis, MO) in 20 ml sterile isotonic saline solution. 
Each cow was randomly assigned to a treatment group. No drug treatment 
was administered to the control group, flunixin meglumine (Banamine®, Schering-
Plough, Union, NJ) at a dose of 2.2 mg/kg was administered to the second group, 
and isofiupredone acetate (Predef ® 2x, Pharmacia Animal Health, Kalamazoo, MI) 
at a dose of 20 mg was administered to the third group. Drug treatments were 
administered intravenously by jugular venipuncture as soon as possible after the 
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development of clinical mastitis, which was defined as measurable mammary 
swelling combined with a rectal temperature of at least 40° Celsius. Clinical 
mastitis developed between 4 and 7 hours following LPS administration in all cows. 
Milk samples for Somatic Cell Count were preserved using bronopol and 
sent by mail to the Iowa Dairy Herd Improvement Association laboratory in 
Dubuque, Iowa, for analysis using a Fossomatic 400 cell counter. Analysis of 
cytokeratin-positive cells was performed at the College of Veterinary Medicine at 
Iowa State University. On the day of collection, samples were washed with 
phosphate buffered saline solution with 0.1% bovine serum albumin and 0.1% 
sodium azide, to remove milk fat and whey. These cell samples were then preserved 
using 1 % paraformaldehyde and refrigerated until staining and flow cytometric 
analysis, which was performed within 48 hours. Just before flow cytometric 
analysis, intracellular staining for cytokeratin was performed by incubating the 
samples with a 0.1% saponin solution and FITC-conjugated monoclonal mouse 
anti-human cytokeratin IgG. Cytokeratin is considered to be a marker of epithelial 
cells in bovine milk (Paape and Miller, 1988). Each sample incubated with anti-
cytokeratin IgG had a paired isotype control sample incubated with FITC-
conjugated mouse IgG. Flow cytometric analysis of forward scatter, side scatter 
and fluorescent staining properties of milk samples was performed using a 
FACScan Flow Cytometer (Becton-Dickinson, Franklin Lakes, NJ). Percentage of 
cytokeratin-positive cells in each sample was multiplied by the total Somatic Cell 
Count in order to calculate the total number of cytokeratin-positive cells per 
milliliter in each milk sample. Data from two cows were discarded from cell 
analysis because their initial Somatic Cell Count was greater than 500,000, so 
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their mammary glands could not be assumed to be free of inflammation prior to the 
administration of LPS. Cell analysis results are presented in Table 1. 
The mean percentage of cells that stained positive for cytokeratin prior to 
the induction of mastitis was 4.177%. Mean Somatic Cell Count prior to mastitis 
induction was 185,700 cells/mL The calculated mean number of cytokeratin-
positive cells per milliliter of milk prior to induction of mastitis was 7711. The 
percentage of cytokeratin-positive cells found in normal milk in this study was 
within the range of values previously reported for epithelial cells in normal milk. 
Paape and Miller (1988) reported a mean value of 16.5% epithelial cells in normal 
milk using Wright's stain and light microscopy, and 17.5% using cytokeratin 
monoclonal antibody staining and light microscopy, while Lee, Wooding and Kemp 
(1979) reported values ranging from 0% to 7% epithelial cells in normal milk using 
electron microscopy. 
Changes in cell populations in the milk in the first 12 hours following the 
administration of LPS were significant. Except for one cow in the isofiupredone 
acetate-treated group, Somatic Cell Count and total number of cytokeratin-positive 
cells per ml were increased in all cows. Mean Somatic Cell Count increased to 
6,332,600 cells/mL, and the percentage of cytokeratin-positive cells increased to 
40.6%. The mean total number of cytokeratin-positive cells per milliliter of milk 
after LPS administration was 2,954,554. These findings are at odds with previous 
work that describes a drop in percentage of epithelial cells in mastitic milk as a 
result of a large influx of neutrophils (Miller et al, 1991). The amount of time that 
had elapsed between the onset of infection and the sampling of milk was unknown 
in the study by Miller et al, and may have been as long as six days. The work of 
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Frost and Hill (1982), which focused on acute changes to the mammary epithelium 
10 or 14 hours after the intramammaiy administration of Escherichia coli is 
congruent with the findings of this study. Frost and Hill found that ten hours 
following the introduction of 50 or 200 Escherichia coli organisms into the 
mammary gland, microscopic examination revealed only mild changes in the 
epithelial layer, but 14 hours post infection there were extensive areas where 
mammary epithelium had been completely denuded and the basement membrane 
was exposed. These desquamated areas were more prevalent lower in the gland, 
with damage concentrated in the teat sinus, less epithelium lost from the 
lactiferous sinuses and little apparent damage to the glandular tissue. 
The behavior of epithelial cells in the current study is consistent with the 
observation of extensive damage to mammary epithelium following administration 
of Escherichia coli into the mammary gland. Damage to the epithelium could be 
expected to occur more quickly with the direct administration of LPS than with the 
administration of 50 or 200 endotoxin-producing bacteria, as it would take time for 
the bacteria to multiply to high enough numbers to produce damaging amounts of 
endotoxin. The high numbers of cytokeratin-positive cells in milk obtained 12 
hours following the administration of endotoxin are likely a result of extensive 
epithelial cell damage and sloughing. Observation of this effect may have been 
enhanced in the current study, as post-mastitis milk samples were obtained by 
stripping a small amount of milk onto the floor, then milking the sample for 
analysis by hand. This may have resulted in the post-endotoxin milk samples 
containing primarily milk from the more greatly affected sinus areas of the gland, 
and very little or no milk from higher up in the less-damaged alveoli of the gland. 
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No effects of drug treatment on the magnitude of change in somatic cell 
counts or percentage of cytokertin-positive cells in the milk were identified using 
the student's t-test for matched pairs in the JMP software program (SAS Institue, 
Cary, NC). 
In summary, in the first 12 hours following the administration of LPS into 
the mammary gland, the percentage and total number of cytokeratin-positive cells 
in milk increased dramatically. This finding is consistent with severe damage and 
sloughing of epithelium in the mammary gland early in the course of endotoxic 
mastitis. Treatment with flunixin meglumine or isofiupredone acetate following the 
development of clinical signs of mastitis did not limit the magnitude of the increase 
in cytokeratin-positive cells in the milk This lack of treatment effect may be 
associated with the drugs not being given until 4 to 7 hours following the 
intramammaiy administration of endotoxin, when clinical signs were detected. 
Future research may be directed at determining when in the course of endotoxic 
mastitis relative numbers of neutrophils begin to exceed relative numbers of 
cytokeratin-positive cells milk, and how sloughing of epithelial cells from the 
mammary gland may affect the course of the disease and subsequent milk 
production. 
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Before LPS Administration After LPS Administration Net Chance 
Cow ID Treatment Cytokeratin Somatic Cytokeratin Cytokeratin Somatic Cytokeratin Cytokeratin 
OfQUD Positive 
1% of cells) Ceil Count 
fx 104 
Positive 
(cells/mL) 
Positive 
(% of cells) 
Cell 
Count 
(X 103) 
Positive 
(cells/mL) 
Positive 
(cells/mL) 
4830 Control 2.25 38 855 4.27 582 24851 +23,996 
4920 Control 7.22 293 21,155 37.28 9421 3512149 +3,490,994 
5319 Control 3.61 284 10,252 88.35 5004 4421034 +4,410,782 
5301 Control 1.62 159 2576 28.29 4632 1310393 + 1,307,817 
4599 Flunixin 12.47 20 2494 1.25 12,794 159925 + 157,431 
5051 Flunixin 7.39 348 25,717 68.19 4809 3279257 +3,253,540 
4924 Isofiupredone 1.47 17 250 68.45 11,036 7554142 +7,553,892 
5294 Isofiupredone 2.12 231 4897 2.69 69 1856 -3041 
4985 Isofiupredone 1.7 25 425 91.68 9108 8350214 +8,349,789 
5307 Isofiupredone 1.92 442 8486 15.87 5871 931728 +923,241 
Mean 
Standard Error of the 
Mean 
4.177 
1.05 
185.7 
44.67 
7711 
2575 
40.632 
10.23 
6332.6 
1208.33 
2954555 
877,719 
+2,946,844 
877,792 
Table 2.1 Results of Somatic Cell Count and Flow Cytometric Analysis of Milk Samples Before and After the 
Administration of Intramammaiy Lipopoly saccharide (LPS) 
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CHAPTER 4. PHYSIOLOGIC AND MILK PRODUCTION EFFECTS OF TWO ANTI­
INFLAMMATORY DRUGS IN COWS WITH ENDOTOXIN INDUCED MASTITIS 
A Paper Submitted to the Journal of Dairy Science 
S. A. Wagner, M. D. Apley 
Abstract 
The effects of two commonly used anti-inflammatory drugs were investigated 
in lactating Holstein dairy cows with mastitis induced by the administration of 
purified bacterial endotoxin. Flunixin meglumine, a non-steroidal anti­
inflammatory drug, or isofiupredone acetate, a steroidal anti inflammatory drug, 
were administered to cows following the development of mammary swelling in the 
affected gland and a rectal temperature of 40 °C or greater. Heart rate, rectal 
temperature, and rumen motility were recorded hourly for 14 hours following the 
intramammaiy administration of endotoxin. Milk production was evaluated for five 
days before and ten days following the day of mastitis induction and drug 
treatment. Neither drug decreased milk production loss nor mammaiy surface 
swelling when compared to untreated mastitic controls. Both drugs reduced the 
mean heart rate in treated groups over the 14 hours following endotoxin 
administration, when compared to untreated mastitic controls. Animals treated 
with flunixin meglumine also had increased rumen motility and decreased rectal 
temperature over the same time period, when compared to untreated mastitic 
controls or mastitic cows treated with isofiupredone acetate. This study suggests 
that both drugs may provide some relief from the pain of mastitis. Until it is known 
whether relief of fever is beneficial or detrimental in naturally occurring cases of 
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infectious mastitis, it is not possible to infer that one agent would be superior to 
the other in the treatment of such cases. 
Introduction 
Mastitis is the most costly disease on modern dairy farms. In addition to the 
expenses of treatment and discarded milk, income is lost because inflammatory 
damage to the mammary gland may temporarily or permanently reduce milk 
production. Limiting inflammation in the mammary gland during an episode of 
clinical mastitis might also limit damage to the gland and preserve milk 
production. 
Previous work has demonstrated that anti-inflammatory drugs may 
ameliorate milk production loss in cows with mastitis induced by the 
intramammaiy administratinn of Escherichia coli bacteria or bacterial endotoxin, 
when the drugs are administered prior to the development of clinical signs 
(Harmon, Shuster et al. 1985; Lohuis, Leeuwen et al. 1988). Unfortunately, in 
practice it is not possible to anticipate mastitis and administer anti-inflammatory 
therapy prior to the development of clinical signs. The study reported here 
compared the effects of two commonly used anti-inflammatory drugs on milk 
production and clinical signs when they were administered to lactating dairy cows 
after the development of clinical signs of mastitis resulting from the intra mammary 
administration of purified bacterial endotoxin. 
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Materials and Methods 
This protocol was approved by the Committee on Animal Care at Iowa State 
University. 
Study Population 
Thirty Holstein cows from the Iowa State University Dairy in Ankeny, Iowa, 
were selected for use in this study. They were selected based on the following 
criteria: 30 to 60 days into second or greater lactation, no clinical mastitis in the 
current lactation, no drug treatment in the previous 30 days, and no abnormalities 
on physical examination. 
Group Assignment and Randomization Procedures 
Cows were randomly assigned to one of three treatment groups: mastitis 
with no drug treatment, mastitis treated with isofiupredone acetate (Predef 2x 
™,Pharmacia Animal Health, Kalamazoo, Michigan) or mastitis treated with 
flunixin meglumine (Banamine®, Schering-Plough, Union, NJ). In order to 
minimize day effects on clinical outcomes, one cow from each of the three 
treatment groups was enrolled in the trial on each trial day. Randomization was 
achieved by assigning a two digit random number from a random number list, read 
in sequence from a random starting point, to each treatment group on each trial 
day. Selected cows were ranked from lowest to highest farm identification number 
and assigned to the group with the random number of the same rank. All clinical 
work for this project was conducted between September 2001 and April 2002. 
Housing and Husbandry 
On trial days, cows were kept in a small bam where they were accustomed 
to spending time while undergoing treatments and routine examinations such as 
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pregnancy diagnosis. They had unlimited access to water and a total mixed ration 
composed primarily of corn silage and dry hay, formulated for lactating dairy cows. 
Cows were caught in headlocks for the hourly recording of clinical observations, 
but were allowed to roam freely in the barn at other times. The cows were milked at 
their normal 12-hour interval. 
Induction of Mastitis 
Cows selected for use in this study had a negative bacterial culture 72 hours 
before the induction of mastitis and a negative California Mastitis Test in the 
treated quarter on the day of their participation the study. The California Mastitis 
Test on the other three quarters had either negative or trace reaction immediately 
before the induction of mastitis. 
Mastitis was induced in the left front quarter by intramammary 
administration of 0.1 mg purified Lipopolysaccharide (LPS) from Escherichia coli 
0111.B4 (Sigma-Aldrich, St-Louis, MO) in 20 mL sterile isotonic saline solution. 
Clinical mastitis was defined as a measurable increase in mammary surface 
area above the baseline measurement, combined with a rectal temperature of 40° C 
or higher. One cow from the untreated control group and one cow from the 
isoflupredone acetate-treated group were removed from the study because they 
failed to develop clinical mastitis as defined above. 
Clinical Variables 
Clinical variables recorded hourly for all treatment groups included rectal 
temperature by electronic thermometer, heart rate by auscultation for 15 seconds 
with a stethoscope, number of rumen contractions per two minutes by 
auscultation of the left paralumbar fossa for two minutes with a stethoscope, and 
66 
mammary surface area. Mammary surface area was measured as follows: after 
removing the hair from the lateral aspect of the left front quarter with electric 
clippers, four marks were made on the udder skin with a permanent marker using 
a rectangular plastic template measuring 100 mm by 120 mm. The distance 
between the marks for each side of the rectangle and both diagonals were 
measured using a flexible plastic ruler. In order to calculate mammaiy surface 
area, the rectangular area being measured was divided by the two diagonals into to 
four triangles, and the area of each triangle was calculated based on the length of 
its three sides using Heron's Formula, which states that the area of a triangle with 
sides of lengths a, b, and c is equal toV«*-«xi-»x-r-c), where s equals a*b + e. The 
2 
areas of the four triangles were summed to total the overall rectangular surface 
area. This method allowed surface area measurements to reflect expansion that 
occurred outward from the initial plane of measurement, in addition to expansion 
within the two dimensions of the created rectangle. 
Study Design 
Following the morning milking, four black marks were made on the udder 
skin of the left front quarter as described above. Each cow was examined and had 
baseline clinical observation values recorded, then LPS was infused into the left 
front quarter. Clinical observations and mammary surface area measurements 
were recorded at fourteen additional hourly time points thereafter. 
Anti- inflammatory treatment was administered to cows in the drug 
treatment groups as soon as possible after the hourly observation at which they 
were noted to have developed clinical mastitis. Both drugs were given intravenously 
by jugular venipuncture; isoflupredone acetate was dosed at 20 mg per cow and 
67 
flunixin meglumine was dosed at 2.2 mg/kg body weight per cow. Body weight for 
all cows was estimated using a girth weight tape. 
Milk Production 
Milk weight data used in this study were collected electronically. Each cow 
in the study wore a computer chip on a neck strap bearing her farm identification 
number. The farm identification number was read from the computer chip by a 
scanner as each cow entered the milking parlor and used to record the cow's 
production at each milking. Cows enrolled in this study had twice-daily milk 
weights recorded for the week prior and three weeks following the day of 
participation in the study. 
Statistics 
All statistical analyses for this study were performed using the JMP 
statistical software program (SAS Institute, Gary, North Carolina). The study design 
provided a power of greater than 0.80 to detect a one-day difference of 10 pounds 
in daily milk weight between groups. Analysis of baseline clinical variables was 
performed using analysis of variance. Subsequent clinical variables and five-day 
baseline milk production data were analyzed using multivariate analysis of 
variance, which accounts for repeated measurements over time. Statistical 
significance was designated a priori as a P value less than or equal to 0.05. 
Baseline clinical observations were considered covariates for statistical analysis of 
clinical variables following treatment, in order to compensate for variation in mean 
baseline measurements between groups. 
initial analysis of milk production during the recovery period using 
multivariate analysis of variance for repeated measures revealed an interaction 
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between time and treatment Further statistical analysis was therefore done using 
analysis of variance separately for each day of the recovery period. Dunnett's 
method was used to correct the tendency toward type 1 error when comparing 
treatment groups individually to the control group. Baseline milk production for 
the five days prior to the study was considered a covariate for statistical analysis of 
milk production recoveiy following mastitis, in order to compensate for variation in 
mean baseline milk production between groups. 
Results 
Physiological Variables 
Rumen contractions. (Figure 1) There was no significant difference between 
groups in baseline rumen contraction frequency (P = 0.5996). Cows treated with 
fiunixin had a higher frequency of rumen contractions during the fourteen hours 
following endotoxin administration than the control group (P = 0.0357) or the 
isofiupredone-treated group (P = 0.0121). There were no significant differences in 
rumen contraction frequency between the control group and the isofiupredone-
treated group (P = 0.4310) 
Heart rate. (Figure 2) Baseline heart rate for the three groups was not different 
(P = 0.2931). Cows receiving drug treatment had a lower heart rate over time than 
untreated controls (P = 0.0019 for fiunixin, P = 0.0274 for isflupreodne). There were 
no significant differences in heart rate between the two drug treatments (P = 
0.1626) 
Rectal Temperature. (Figure 3) Mean baseline temperatures for all groups 
were not significantly different (P = 0.5262). Cows treated with flunixin had lower 
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rectal temperatures over time than did isofiupredone-treated (P =0.0023) or 
untreated (P = 0.0017) cows. Differences in rectal temperature between the 
isofiupredone-treated and control groups did not achieve statistical significance (P 
= 0.0960) 
Mammary Surface Area. (Figure 4) There were no significant differences 
between any of the three groups in baseline measurements of mammary surface 
area ( P = 0.6971) or changes in mammary surface area over the 14 hours following 
the introduction of LPS into the mammary gland (P= 0.1757). 
JffiZfc Production. (Figure 5) Baseline milk production for the five days 
preceding the induction of mastitis was not significantly different between groups 
(P = 0.2436). By the 10th day following the induction of mastitis, each treatment 
group had recovered to pre-challenge mean milk production. There were no 
significant differences between groups in the rate of recovery of milk production (P 
> 0.05 for all days during the recovery period). 
Discussion 
Fiunixin meglumine and isofiupredone acetate are commonly used drugs in the 
treatment of inflammatory conditions of dairy cows in the United States, and both 
drugs are available in preparations that are approved for such use. Fiunixin 
meglumine is a non-steroidal anti-inflammatory drug, while isofiupredone acetate 
is a corticosteroid drug with primarily glucocorticoid anti-inflammatory activity. 
It has previously been established that fiunixin meglumine provides relief of 
clinical signs such as fever, local swelling, decreased rumen motility and 
depression in mastitis induced using Escherichia coli bacteria or bacterial 
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endotoxin (Anderson, Smith et al. 1986; Lohuis, Leeuwen et al. 1989). In toxic 
mastitis due to natural infection with Escherichia coli. Klebsiella species, and other 
organisms, however, fiunixin meglumine was not shown to affect the rate of 
bacterial cure or subsequent milk production (Dascanio, Mecher et aL 1995). 
Isofiupredone acetate, in contrast, has received little published attention as a 
therapy for endotoxic mastitis, despite its labeled approval for use to treat 
inflammation and infection in cattle, and evidence that other steroidal anti­
inflammatory drugs may relieve clinical signs in endotoxin-induced mastitis 
(Lohius, Leeuwen et aL 1989) and reduce milk production loss in cows with 
mastitis induced by the intramammary administration of Escherichia coli bacteria 
(Lohuis, Leeuwen et aL 1988). One previous study did not show a reduction in milk 
production loss due to endotoxin-induced mastitis when isofiupredone acetate was 
administered after the development of clinical signs (Wagner and Apley In Press). 
The objective of the current study was to directly compare these two commonly 
used drugs using an endotoxin-induced mastitis modeL Unlike much previous 
research involving anti-inflammatory drugs and mastitis, treatment was not 
administered until after local and systemic clinical signs of mastitis had developed. 
Cows which failed to develop mastitis of a severity that would warrant treatment 
were it seen in practice were discarded from the study. 
Even when administered following the development of clinical signs, fiunixin 
meglumine did alleviate most signs over the remainder of the acute phase in which 
they were measured. Despite providing no measurable reduction in local mammary 
swelling, fiunixin did preserve rumen motility and reduce fever and heart rate in 
cows with endotoxic mastitis, when compared to untreated controls. Isofiupredone 
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did not affect local swelling, rumen motility, or rectal temperature when compared 
to untreated controls, but it did reduce heart rate equally to fiunixin. Neither drug 
had a significant effect on milk production following the mastitic episode. 
Making inferences about anti-inflammatory treatment of naturally occurring 
endotoxic mastitis based on the results of this study and other studies involving 
these two drugs is difficult There are differences between endotoxin-induced and 
infectious disease; fatal disease may occur due to infection with Escherichia coli 
bacteria but is extremely unlikely using the endotoxin-induced model, and 
endotoxin-induced mastitis has different effects on cells and cytokine production 
than natural infection (Oostveldt, Tomita et aL 2002). In naturally occurring 
disease, neither therapy has been shown to affect the clinical outcome, but there 
are other worthwhile therapeutic objectives that may be investigated using the 
endotoxin model, such as the relief of pain, reduction of local swelling, and 
preservation of milk production. 
Both of the agents investigated here reduced mean heart rate in treated 
mastitic cows, when compared to untreated control groups. Heart rate may rise 
due to fever or pain; however, only fiunixin meglumine significantly reduced fever 
in this study, so one might conclude that heart rate reduction in this study is an 
indicator of pain relief. Previous research using isofiupredone acetate to treat 
endotoxic mastitis demonstrated a rise in heart rate in treated cows compared to 
untreated controls; however, in the previous study only treated cows were having 
repeated jugular venipuncture, the stress of which is likely the reason for increased 
heart rate (Wagner and Apley In Press). 
Fever reduction has traditionally been a goal of anti-inflammatoiy therapy, but 
recent human literature has suggested that this may not be a valid goal, and in 
humans antipyretic therapy may actually extend the duration of infectious disease 
(Mackowiak 2000). Fever reduction in the therapy of mastitis in daiiy cows may be 
beneficial or detrimental; there is no published research to support either 
proposition. It is therefore difficult to judge the value of the fever-reduction 
properties of fiunixin meglumine or the absence of such activity by isofiupredone 
acetate in endotoxic mastitis in daiiy cows. 
In conclusion, the results of this study, when considered in concert with 
previous research into the effects of these two drugs in cows with endotoxic 
mastitis, may raise more questions than they answer. Fiunixin meglumine 
preserves rumen motility while isofiupredone acetate does not, but this difference 
did not translate into improved milk production following either treatment These 
two drugs differ significantly in their effects on fever, with fiunixin meglumine 
quickly reducing fever in treated cows and isfiupredone acetate-treated cows 
showing no reduction of fever when compared to untreated controls. Whether fever 
reduction is beneficial in the therapy of endotoxic mastitis is unknown; it can be 
said that reduction of fever is not correlated with accelerated recovery of milk 
production in cows with endotoxin-induced mastitis. Despite the absence of 
measurable reduction in mammary gland swelling for either agent, both 
isofiupredone acetate and fiunixin meglumine did reduce heart rate in treated 
animals, which may indicate that both agents provide some relief of pain in cows 
with endotoxin-induced mastitis. 
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CHAPTER 5. GENERAL CONCLUSIONS 
The objectives of the research presented herein were to describe the effects 
of fiunixin meglumine, a non-steroidal anti-infiammatoiy drug (NSAID) and 
isofiupredone acetate, a corticosteroid drug, on the clinical and cellular changes 
caused by endotoxic mastitis in daiiy cows, using an endotoxin-induced mastitis 
model Unlike much previous work done to investigate anti-inflammatory therapy 
of endotoxic mastitis, in the studies reported here the administration of drug 
therapy followed, the development of local and systemic clinical signs. In many of 
the previous studies done using an infectious or endotoxic model of naturally 
occurring endotoxic mastitis, anti-infiammatoiy drugs were administered either 
concurrently with the agent used to induce the mastitis or at a set time after the 
administration of the agent, instead of in response to clinical signs, as would be 
done in a clinical setting. 
In the first study, the steroidal drug isofiupredone acetate was given to 
healthy cows and cows with endotoxin-induced mastitis, at the label dose of 20 mg 
per cow. Unlike the steroidal drug dexamethasone, which has been shown to 
ameliorate milk production losses when given to cows with induced mastitis prior 
to the development of systemic clinincal signs, isofiupredone administered after the 
development of clinical signs did not have a protective effect on milk production. 
The drug also did not relieve local or systemic clinical signs of endotoxic mastitis. 
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In the second study, isofiupredone acetate and the NSAID drug fiunixin 
meglumine were investigated for their ability to limit the degree to which mammary 
epithelial cells were sloughed into the milk during the acute phase of endotoxin-
induced mastitis. This study demonstrated a marked increase in the numbers and 
percentage of epithelial cells in the milk of cows within the first 12 hours following 
the administration of endotoxin, but the magnitude of the increase was not affected 
by administration of either drug. 
The final study compared the effects of fiunixin meglumine and 
isofiupredone acetate when administered following the development of clinical 
signs to cows with endotoxin-induced mastitis. Neither drug relieved mammary 
gland swelling or milk production loss. Both drugs reduced heart rate in treated 
cows, suggesting that both drugs provided pain relief. Isofiupredone acetate did not 
relieve elevated heart rate in the first study, but this was likely due to the 
concurrent serial venipuncture performed on treated cows, to which untreated 
cows were not subjected. Fiunixin meglumine also reduced rectal temperature and 
increased rumen motility during the acute phase when compared to untreated 
controls. 
No well-designed or well-reported study has documented increased survival 
of naturally occurring endotoxic mastitis following treatment with any anti­
inflammatory agent. Until it is known whether reduction of fever is beneficial, 
detrimental, or of no influence in the outcome of infectious mastitis, it cannot be 
concluded that the fever reduction property of fiunixin meglumine makes it a better 
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choice for such therapy. Neither can isofiupredone be recommended as a superior 
treatment, as its administration at the label dose in response to clinical signs of 
mastitis has not demonstrated benefits to milk production, as were observed when 
the steroidal drug dexamethasone was given prior to the onset of clinical mastitis. 
It can, however, be concluded from the research described herein that either 
fiunixin meglumine or isofiupredone acetate will provide humane relief of the pain 
associated with mastitis. The use of one of these agents in the treatment of mastitis 
may be recommended based on this finding alone. 
Although neither drug was found to protect milk production in cows with 
endotoxin-induced mastitis when given at the label dose after the development of 
clinical signs, further investigation, especially of isofiupredone acetate, might be 
warranted. Future work might be directed at investigating a higher dose of 
isofiupredone acetate, as it is not as potent as dexamethasone, which was found to 
protect milk production when given prior to the development of clinical signs of 
induced mastitis at a dose of 12.5 to 30 mg for a 500 kg cow. Isofiupredone is 
described as being about one third the potency of dexamethasone, so an equivalent 
amount of glucocorticoid potency would be achieved by a dose of 37.5 to 90 mg for 
a 500 kg cow. Another approach would be to investigate dexamethasone itself, at a 
similar dose to those used in previous studies on induced-mastitis models, but 
administered after the development of clinical signs instead of before clinical signs, 
as done by previous researchers. 
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Further research into the question of whether fever reduction in cows with 
endotoxic mastitis is beneficial to survival and subsequent milk production would 
also be warranted, ideally in cows with naturally-occurring infectious mastitis. The 
observation that the NSAID drug fiunixin meglumine reduces fever in cows with 
endotoxic mastitis while the steroidal drug isofiupredone acetate does not, suggests 
that these two agents might be appropriate for use in such a study. 
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APPENDIX A. REPRESENTATIVE FLOW CYTOMETRY DATA 
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Figure A2. 
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Figure A4. 
Cytokeratin-linked FITC Stain 
After Endotoxin Administration 
Forward Scatter (FSC), plotted here on the X axis, is considered a measurement of cell size. 
Side Scatter (SSC), plotted here on the Y axis, is considered a measurement of the 
granularity of cell contents. Plots FSC vs. SSC, as seen above, did not depict clearly 
differentiated cell populations in any of the milk samples. All data presented in this 
appendix are from the same cow. 
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Figure A6. 
Cytokeratin-linked FITC Stain 
Before Endotoxin Administration 
Unlike FSC vs. SSC plots, these plots of natural fluorescence (on the Y axis) versus 
intensity of FITC fluorescence do clearly identify different cell populations. The FITC 
stain was linked to anti-cytokeratin antibody in samples identified as "Cytokeratin-
linked FITC Stain", and to mouse IgG in samples identified as "Control Milk Cells'. Rl, 
shown in Figure A5, is a gate drawn by the investigator to measure the number of cells 
in one population. One can see from these plots that the population of cells contained 
within the gate is present in the stained sample but not in the control sample. The 
population of cells within gate Rl is therefore considered to be mammary epithelial 
cells, as they are the only cells in milk which can be expected to bind anti-cytokeratin 
antibody. This is borne out by the count of cells within the gate measured by the flow 
cytometer. The percentage of gated cells in the sample containing anti-cytokeratin 
linked FITC stain is 7.39%, while only 0.53% of cells in the control sample with FITC 
linked to unspecific mouse IgG are contained within the gated area. Gate 1, as drawn in 
Figure AS, remains the same throughout all of the data presented here. 
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Figure A7. 
Control Milk Cells (Unstained) 
After Endotoxin Administration 
Figure A8. 
Cytokeratin-linked FITC Stain 
After Endotoxin Administration 
Following endotoxin administration, the natural fluorescence vs. FITC fluorescence plots 
do not depict separate cell populations clearly, as they did in the same cow prior to the 
onset of mastitis (Figures AS and A6). Still, analysis of cell counts inside gate Rl, which 
was drawn using the pre-endotoxin samples, reveals that there is a population of cells 
present in the stained sample that is not present in the control sample; 68.19% of cells in 
the stained sample are within the gate, while only 0.32% of cells in the control sample from 
the same cow are within the gate. 
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Histograms are another useful way to examine flow cytometry data. Figure A9 is a 
histogram plot of cells in milk samples taken after endotoxin administration. The solid area 
is the count of cells vs. FITC fluorescence for the control sample. The lighter grey line is an 
outline of the same plot for the anti-cytokeratin stained sample. The mean amount of 
fluorescence by the cells in the stained sample is clearly greater than that of the control 
sample, as the area contained in the plot is further along the X axis, FITC fluorescence. 
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Figure A10. 
Figure AlO is a histogram plot in the same format as Figure 9, but including only the cells 
contained in gate Rl. The solid area containing the count of gated cells in the control 
sample is very small. The area contained in the lighter grey line, representing gated cells in 
the stained sample, is much larger and centered farther along the X axis than the gated 
cells in the control sample. This reflects the higher number of gated cells in the stained 
sample, and their greater intensity of FITC fluorescence. 
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APPENDIX B. SUMMARY OF ATTEMPTS TO QUANTIFY ISOFLUPREDONE IN 
THE SERUM OF DAIRY COWS FOLLOWING INTRAVENOUS ADMINISTRATION 
OF ISOFLUPREODNE ACETATE 
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As mentioned briefly in Chapter 1, one of the original objectives of the first 
study described in this dissertation was to describe the pharmacokinetic behavior 
of isoflupredone acetate in healthy cows and cows with endotoxin-induced mastitis 
following the administration of 20 mg of the drug intravenously. The 
pharmacokinetic portion of the study was never executed due to difficulties 
encountered with the quantification of drug in bovine serum. This appendix 
describes the procedures that were performed in the laboratory in an attempt to 
quantify the drug in bovine serum. 
In the autumn of 2000, a pilot study was done in which one cow had blood 
samples drawn before and after the administration of isoflupredone acetate. These 
samples were centrifuged and serum was removed and saved for analysis. 
Quantification of isoflupredone was performed using High Performance Liqiud 
Chromatography (HPLC) and Immunohistochemistry (IHC). Results of these 
analyses are given in Tables B1 and Table B2. 
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Table Bl. Results of Immunohistochemical Analysis of Serum Samples From 
The Pilot Cow (in Parts Per Billion). 
In this table, "Unk 01" is the serum sample taken prior to the 
administration of isoflupredone acetate, and "Unk 02" through "Unk 08" are serial 
serum samples taken following drug administration. Measured drug concentration 
is negligible for the sample taken prior to drug administration, then there is an 
increase followed by a decrease in a drug levels over time, with drug levels at the 
time of sample "Unk 08" undetectable. Positive and negative control and blank 
plasma measurements appear to have appropriate analytical results. 
Unknown (ngAml) 
t ;  v .Mi  î rm i'i11.1 ' 
UNICOI A1 
A2 
0.383 
0.382 
1.068 
1.148 
1.108 0.054 4.9 
UNK02 81 
B2 
0.270 
0.282 
31.708 
. 25.341 
26.525 4.502 15.8 
UNK»* CI 
C2 
0.258 
0.262 
30.057 
43.731 
41.194 9.568 6.7 
UNKQ4 01 
02 
0.245 
0.267 
49.380 
33.488 
41.439 11.243 27.1 
UNK05 El 
Q 
0.280 
0.201 
26.324 
21.268 
23.796 3.575 15.0 
UNK06 F1 
F2 
0.320 
0.335 
11.383 
7.755 
9.559 2.551 26.7 
UNK07 Q1 
02 
0.357 
0.415 
3.882 
Ranoe? 
3.882 0.000 0.0 
UNKOt H1 
H2 
0.453 
0.441 
Range? 
Ranoe? 
Range? Range? Range? 
UNK06 H7 0.071 0.000 0.0 
UNK10 H6 0.370 2Ï26» 555» 0.000 0.0 
UNK11 HO 
H10 
0.418 
0.432 
Range? 
Ranoe? 
Range? Range? Rmnge? 
R - OuMde standard range 
Mean Adhwted Result: Error 
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••rum sample 1st analysée 2hd analyste 3rd anatyete Average, 
1 23.2 21 22.1 J 
2 29.3 37.5 33.4 
3 48.9 53.2 51.2 
4 48.2 45.8 47 
5 29.5 24.1 26.8 
6 13 18.9 18 
7 10.5 8.4 9.5 
8 0 5.8 4.3 3.4 
Table B2. Results of High Performance Liquid Chromatography Analysis of 
Serum Samples From The Pilot Cow (in Parts Per Billion). 
As with the samples analyzed using Immunohistochemistiy, sample 1 was 
taken prior to the administration of isoflupredone acetate, and samples 2 through 
8 were taken in sequence following drug administration. The results using HPLC 
were similar to those obtained using IHC, with the notable exception that the 
samples taken prior to drug administration appeared to have significant levels of 
the drug. This was considered an artifact of the analysis, as the cow in question 
had been carefully screened to be sure she was not exposed to the drug prior to its 
administration as a part of this project. Based on results of HPLC and IHC analysis 
in the pilot study, it was decided that IHC would provide the most accurate 
analysis of serum drug levels. 
In the late spring of 2001, the first serum samples for use in the study were 
obtained from cow number 4598 and analyzed using Immunohistochemistry. 
Results of that analysis are given in Table B3. 
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Unknown (ng/ml) 
Su» 
UN KOI A1 
A2 
0.778 
0.814 
Range? 
Ranoe? 
Range? Range? Range? 
UNK02 B1 
82 
0.674 
0.744 
Range? 
Ranoe? 
Range? Range? Range? 
UNK03 CI 
C2 
0.714 
0.777 
Range? 
Ranoe? 
Range? Range? Range? 
VNK04 D1 
02 
0.611 
0.692 
Range? 
Ranoe? 
Range? Range? Range? 
UMKOS El 
E2 
0.978 
0.818 
Range? 
Ranoe? 
Range? Range? Range? 
UNK06 Ft 
F2 
0.914 
0.802 
Range? 
Ranoe? 
Range? Range? Range? 
UNK07 G1 
02 
0.859 
0.802 
Range? 
Ranoe? 
Range? Range? Range? 
UNK08 H1 
H2 
0.806 
0.840 
Range? 
Ranoe? 
-Range? Range? Range? 
UNK09 A3 
A4 
0.689 
1.002 
Ranpa? 
Ranoe? 
Range? Range? Range? 
UNK41 AG 0.267 8.721 6.347 0.529 6.3 
A7 0.274 - 7.973 — 
UNK42 B6 
87 
0.361 
0.347 
3.275 
3.716 
3.495 0.312 8.9 
UNK43 C6 
07 
0.336 
0.375 
4.116 
2.895 
3.505 0.863 24.6 
R - Outside standard range 
Table B3. Results of IHC Analysis of Serum From Cow 4598. 
As in previous figures, sample lwas taken prior to drug administration and 
samples "Unk 02"through "Unk 09" samples were taken in sequence following drug 
administration. "Unk 41" through "Unk 43" are samples with known amounts of 
isoflupredone added to them. The samples with isoflupredone added to them did 
have measurable drug levels in them , however IHC analysis did not detect the 
drug in any of the serum samples. 
Because IHC analysis failed to detect isoflupredone in any of the samples 
taken from the drug treated cow 4598, the same samples were re-analyzed using 
HPLC. Results of that analysis are given in Table B4 and Figure B5. 
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Mnimtampto 1st analysis 2nd analysée 3rd analysis Average 
1 0 0 0 
2 8.6 10 13.1 10.6 
3 16.2 11.8 13.6 13.9 
4 6.8 9.8 4.5 7 
5 3 4.3 3.9 3.7 
6 4.4 Z2 2.1 2.9 
7 3 0 4.3 2.4 
8 4.4 0 1.9 2.1 
9 1.5 8.4 10.1 6.7 
Table B4. Results of HPLC Analysis on Cow 4598 (in Parts Per Billion) 
Unlike IHC, HPLC did detect isoflupredone in the serum of cow 4598. Drug levels 
were lower overall than those found using HPLC in the pilot cow, but the problem 
of detecting the drug in samples taken prior to drug administration appeared to 
have been resolved. 
Table B5 and Figure B6 compare HPLC analysis of sera from the pilot cow and 
from cow 4598. 
imp! 
Pitof-
s Avusqs 
1546 
Avsregi 
1 22.1 0 
2 33.4 10.6 
3 51.2 13.9 
4 47 ' 7 
5 26.8 3.7 
6 16 2.9 
7 9.5 2.4 
8 3.4 2.1 
9 6.7 
Table BS. Comparison of HPLC Results from Pilot Cow and Cow 4598 (in Parts 
Per Billion) 
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Figure B6. Graphic Comparison of HPLC Results From Pilot Cow (#1) and Cow 
4598 (#2) 
As described above, HPLC on Cow 4598 gave results of overall lower drug 
concentrations, but the problem of "false positive" results appeared to have been 
resolved. It was therefore decided that analysis of sera from cows in the 
pharmacokinetic study would begin in earnest using HPLC. Results from the first 
batch of sera analyzed using HPLC are given in Table B7. 
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Isoflupredone Levels in Parts Per Billion 
Cow 
Number 
1 2 3 4 5 6 7 8 9 
4104 nda nda nda nda 8.2 nda nda nda nda 
4623 9.9 12.7 15.9 5.6 2.4 nda nda nda nda 
4787 10.8 19.9 23.4 11.6 nda nda nda nda nda 
4836 13.7 13.4 16 2.7 nda nda nda nda nda 
4723 nda 5 4.3 0.7 nda nda nda nda nda 
4963 13.3 11.7 14.5 10.9 4 nda nda nda nda 
4577 10.6 16.4 15.2 9.1 0.9 nda nda nda nda 
5012 nda nda nda nda nda nda nda nda nda 
4620 20.9 13.5 14.3 11 1.6 nda nda nda/2.5 nda 
Table B7. Results of HPLC on First Batch of Pharmacokinetic Study Cow Sera 
(in Parts Per Billion) 
The results shown in Table B7 were problematic. The primary concern was 
that HPLC analysis detected quantities of isoflupredone in the first serum sample 
in 6 of 9 cows. As with previous examples, this serum sample was obtained prior to 
administration of the drug. It was considered extremely unlikely that the samples 
were contaminated or that the cows already had the drug in their system. Great 
care was taken with sample handling on the farm and in the laboratory, and good 
records of drug treatment were kept for the cows and carefully reviewed prior to 
their admission to the study. It was therefore concluded that these false positive 
results were most likely due to some other analyte registering as isoflupredone in 
the serum upon analysis with HPLC. It was also unusual that one cow never had 
detectable levels of the drug according to HPLC and one cow only had detectable 
drug levels at one time point, but this concern has not yet been addressed, as the 
issue of false positives was made first priority. It was decided that some of the cows 
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with false positive results would have serum drawn and retested using HPLC, 
without any concurrent administration of isoflupredone acetate. Results are given 
in Table B8. 
unyblD mnm H Itom euro » ppb %iec. 
AGN neta 
•M4A 
water 
no# 
e 3.15 31.50 63.00 
ptiwne 1 12 0.47 4.70 
ptaena 1 7.8 3.07 30.70 52.00 
p**m#2 1.3 0.51 5.10 
pfMma2«* e 3.64 35.40 60.60 
ptewni3 2 0.79 7.90 
pW*na3epk 9.9 3.69 36.90 82.00 
•arum 1A 1.3 0.61 8.10 
••rum 1B ndm 0.00 
••rum lB#pk 82 3.23 32.30 64.60 
••rum 2A 1.9 0.76 7.50 
aarum2B 1.4 0.65 5.50 
••rum 2B epic 6.9 3.50 35.00 89.00 
••rum 3A 3.4 1.34 13.40 
munSB 1.1 0.43 4.30 
aenmSB** 9.5 3.74 37.40 66.20 
wrum4A nde 0.00 
mum 4B 1.6 0.71 7.10 
••rum 48 «pk 10.6 4.13 41.30 66.40 
Table B8. Results of HPLC Analysis on Serum Prom Cows That Previously 
Tested Positive For Isoflupredone Prior to Drug Administration (in Parts Per 
Billion) 
Upon re-analysis using HPLC, most of the serum samples from these cows 
again showed the presence of isoflupredone, despite the cows having no known 
timely exposure to the drug. It was therefore decided that serum from two of the 
cows (which provided samples 2A and 4A in Table B8) would be further analyzed 
using Mass Spectrometry, in an attempt to isolate the analyte causing the false 
positive results in HPLC analysis. 
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When analyzed using Mass Spectrometry, serum from both of the cows was 
found to have a spike at the molecular weight of isoflupredone, despite sound 
evidence that neither cow had been exposed to isoflupredone recently enough to 
have detectable levels in her serum. The first test, in which the drug was 
administered as part of the initial pharmacokinetic study, had been several months 
prior to the Mass Spectrometry analysis, and the cows had not, according to farm 
records, been treated with the drug since. There is no reason to believe the farm 
records were incomplete, and furthermore isoflupredone is uncommonly used on 
the farm in any case. 
Results of Mass Spectrometry are shown in Figures Blla through B1 Id. 
Figure B9. Mass Spectrometry of a Serum Sample With Isoflupredone Added 
When Isoflupredone is added to serum, a "spike" in the Mass Spectrometry 
output is seen at 8.13 to 8.14 (circled areas). 
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Figure Bllb. Mass Spectrometry on Serum From a Cow (2A) With False 
Positive Results Using HPLC 
The results of Mass Spectrometry on this cow show spikes at exactly the 
same molecular weight as is seen in serum samples with added isoflupredone 
(circled areas). 
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Figure Bile. Mass Spectrometry on Serum From a Cow (4A) With False 
Positive Results Using HPLC 
Again, this cow has spikes at the same points that they would be expected 
in a serum sample to which isoflupredone had been added 
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Figure Blld. Mass Spectrometry on Solvent Without Isoflupredone Added 
The spike around molecular weight 8.13-8.14 is not seen in this sample of 
solvent with no isoflupredone added (circled areas). 
As with HPLC, Mass Spectrometry could not distinguish between an analyte 
in the serum of certain untreated cows and isoflupredone acetate. Current work is 
focused on finding a way to separate the false analyte from the serum prior to 
HPLC analysis for isoflupredone, using a specialized solid-phase cleanup column. 
